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General introduction and thesis outline
A.S. Sediq, M.R. Nejadnik, W. Jiskoot
Division of Drug Delivery Technology,              BioTherapeutics, Leiden Academic Centre for 
Drug Research (LACDR), Leiden University, Leiden, The Netherlands 
Cluster
Since the early encounters of humans with snakebites, it was obvious that the parenteral 
route is a very pronounced and probably efficient way of drug administration. This observation 
and the use of poisoned arrows by ancient tribes were followed by the experiments of Sir 
Christopher Wren in the 17th century. With the use of a bladder and quill for a syringe 
and needle, he injected wine, ale, opium and other substances into the veins of dogs 
and studied their effects1. Over the following centuries, technological improvements and 
increasing knowledge of physiology and pharmacy resulted in the development of injections 
and infusions as routine medical practices in hospitals. 
Direct injection and infusion into the blood provide rapid action compared with other 
routes of administration where the drug has first to be absorbed. These methods allow 
for achievement of optimum levels of the drug in the blood accurately and immediately. 
Possibility of application of injections in case of unconsciousness or uncooperative state 
of the patient is another advantage of these methods. Additionally, drugs that undergo 
inactivation after oral administration are better off through injection or infusion. The latter is 
especially the case for therapeutic proteins and peptides, which are vulnerable to proteolytic 
degradation in the gastro-intestinal tract, besides being poorly absorbed.  
Although the highly efficient protective barriers in other routes of administration (e.g., skin 
and mucous membranes) are circumvented with injections and infusions, the introduction of 
microorganisms, impurities and other toxic agents can be an accompanying risk for these 
methods of delivery. Therefore, parenteral preparations must be as impeccable as possible 
with respect to purity, freedom from toxicity and contamination. Specifically for therapeutic 
protein products, sub-visible particles (SVP) have received a lot of attention as impurities in 
protein formulations2. These impurities in therapeutic protein drug products are divided into 
two well-studied categories: protein aggregates and non-proteinaceous particles originating 
from packaging materials or excipients3,4. Due to importance of the issue, several methods 
have been developed that allow for quantification and characterization  of SVP and visible 
particles5.  
These methods are also used for characterization of particulate drug delivery systems 
(DDS) that are by design based on SVP6. Many types of particulate DDS are available that 
differ by the site of drug action and the method of particle delivery (local vs. systemic). The 
performance of DDS depends on their size, shape and surface characteristics7,8. Therefore, 
characterization of these systems with high accuracy and detailed output is crucial in the 
formulation development and the overall safety and efficacy of the DDS in the clinic.  
More recently, cell therapy products have entered the pharmaceutical arena9. In 
this case the drug substances themselves, i.e. the cells, are SVP10. As the clinical 
safety and effectiveness of these products depend on the concentration and viability 
of cells, it is of utmost importance to have quantification and characterization 
methods in place during manufacturing, product distribution and prior to administration. 
This thesis deals with the characterization of SVP in the above-mentioned types of products. 
Below, these products are briefly discussed together with the role of analytical techniques 
used to characterize SVP in these products. The last section of this chapter provides a 
short description of the aims and outline of this thesis. 
Therapeutic protein formulations                                                              
The highly specific and complex function of a protein cannot be mimicked by small 
molecules; therefore, therapeutic proteins have prominent advantages over small molecule 
drugs in terms of functionality. In principle, a protein’s functionality is accompanied by a 
highly specific action and less adverse effects as compared to small molecules11. During 
the past few decades, protein therapeutics have becomeincreasingly important for the 
treatment of chronic and life-threatening diseases and conditions. In the year 2013, a total 
number of 338 monoclonal antibodies, 20 interferons, 93 other recombinant proteins and 
250 vaccines were reported to be in various phases of clinical trials12. 
The complex and large structure of these macromolecules, however, make them susceptible 
to conformational changes in the structure of the protein. These changes may occur during 
the production of the bulk substance, the formulation, storage, transportation or other 
treatments that a protein goes through. Conformational changes can among others lead 
to aggregation of the protein in solution13. The presence of aggregated therapeutic protein 
greatly compromises product quality and potentially drug safety14. Presence of aggregates 
has been linked to reduced drug efficacy, serious adverse effects and even death15. One 
needs to clarify the currently accepted nomenclature for differently sized aggregates. 
Considering the fact that aggregates are particulate species we extend this nomenclature 
further into other injectable systems discussed throughout this thesis. Visible particles are 
classified as particles seen during visual inspection, typically above 100 µm. Particles in 
the micrometer range that are not detected during visible inspection are called SVP 
(1 – 100 µm). The nanometer range is divided into the submicrometer range 
(100 – 1000 nm) and the nanometer range (size-exclusion chromatography high-molecular-
weight species) (< 100 nm)16. The particles that appear in therapeutic protein products in 
the SVP range can, in turn, be assigned into three categories: (1) extrinsic particles or 
contaminants (materials that are not part of the drug product, package and/or process); (2) 
intrinsic particles (undesirable, non-proteinaceous materials related to the manufacturing, 
packaging and/or devise itself); and (3) inherent particles (protein aggregates or formulation 
components). Particulate impurities other than protein aggregates, such as excipients 
and packing materials, can influence the product quality as well. For instance, sugars of 
pharmaceutical-grade quality17 and surfactants (such as polysorbate 20)18 have been
shown to be the source of particulate impurities in drug products. Another example of intrinsic 
particulate impurities are silicone oil droplets which leach into the protein solution from the 
glass barrel and the plunger of prefilled syringes19. These droplets can get coated with the 
protein from the solution and agglomerate to increase turbidity in the protein solution20,21. 
The latter example of the silicone oil droplet induced agglomeration in protein solution 
highlights the heterogeneous composition of particles in therapeutic protein products22. 
In addition, SVP are often a very heterogeneous population of micron sized aggregates, 
which in case of protein aggregates can consist of subpopulations of reversible, native 
aggregates and irreversible, unfolded aggregates16. 
The use of analytical tools to count, size and identify the type of particles in therapeutic 
protein products is the most crucial component of understanding and controlling the 
presence of these species. The complexity in composition and subpopulations, as sketched 
above, brings several analytical challenges to the process. In addition, the choice of the 
analytical method for characterization of SPV depends on the stage of development, which 
determines the available amount of the product under consideration. The measurement 
principle of the techniques used for characterization of protein aggregates, determines the 
boundaries and limitations of each particular technique. Many of these techniques are able 
to size and quantify SVP in solution, but not to identify the composition or nature of the 
particle (e.g., proteinaceous or non-proteinaceous). To overcome analytical limitations and 
boundaries for characterization of protein aggregates, it makes sense to combine methods 
with different underlying principles23. 
Controlled release formulations
With respect to DDS we limit our work and discussion in this thesis to controlled release 
formulations in the SVP range, in particular microspheres. Microspheres are here defined 
as particulate systems where the drug is dispersed in the matrix of a carrier material. The 
aim of these drug products lies in the improvement in safety and/or efficacy of an active 
pharmaceutical ingredient (API). Rate-controlled and targeted release is often used as a 
tool to avoid toxic levels of an API in plasma while maintaining therapeutic concentrations 
for prolonged periods of time. 
The aim of the STW project number 12144 was to develop a novel process for the coating of 
dry protein-containing cores with a shell consisting of oppositely charged polyelectrolytes 
(polymers containing charged or ionizable groups), and subsequently analytical methods to 
characterize and evaluate the performance of these DDS. Therefore in this thesis, particle 
characteristics of DDS based on hydrophilic polyelectrolyte complexes and hydrophobic 
polymers are studied. In polyelectrolyte complexes, the (mainly) electrostatic driven 
interaction of the polyelectrolyte (polymers containing charged or ionizable groups) with 
the drug can lead to formation of controlled release particulate systems30. In the category 
of hydrophobic drug carriers, poly lactic-co-glycolic acid (PLGA) is currently the most 
studied for small molecules and biologics, with almost 10 marketed drug products31. The 
great advantage of PLGA is its biocompatibility and biodegradability32 and the ability to 
modify the hydrophobicity by changing the lactic acid / glycolic acid ratio of the polymer33. 
Particle characteristics are important quality attributes of microparticulate DDS that could 
affect the clinical performance of the product37,39.  For instance, the size and shape of the 
particles affect important quality parameters of product, such as release rate of the drug37. 
Moreover, particle porosity has been reported to influence the loading and kinetics of the 
drug release38. The latter will also be influenced by the extent and strength of interactions 
between the polymer and the drug. 
Different techniques are available for studying shape, surface morphology and porosity of 
microspheres. Optical microscopy and scanning electron microscopy (SEM) are probably 
the most employed methods for studying particle shape, size and surface morphology. 
With respect to the measurement of the average size of microspheres, laser diffraction 
(LD) techniques are widely used as well. For the measurements of porosity, techniques 
employing gas adsorption and mercury intrusion are commonly used. In addition, SEM can 
be used to determine porosity when cryo-cutting techniques are used as a pretreatment for 
the particle-containing sample. 
Cell therapy products
This field of pharmaceutical product development has its roots in human stem cell 
therapy and tissue and organ transplantations. Two main principles by which cells 
facilitate therapeutic action are recognized: (1) engraftment, differentiation and long term 
replacement of damaged tissue40 and (2) release of cytokines, chemokines and growth 
factors to facilitate self-healing of an organ or region41. Currently a variety of products from 
multiple cell sources are approved for use42. 
An important quality attribute of cell therapy products (CTP) is the concentration of viable 
cells, which in general are required to obtain the desired effect. These attributes (together 
with a purity and surface marker evaluation) are characteristics to be tested during different 
stages of CTP development. Moreover, in clinical practice the viability of the product needs 
to be attained before administration43. As the manufacturing of CTP is becoming more 
sophisticated and complex, certain institutions, such as the US-based National Institute of 
Health (NIH) and National Heart, Lung and Blood Institute (NHLBI) have designed a so-
called Production Assistance for Cellular Therapies (PACT) program to support researchers 
with the manufacturing44. 
From a formulation point of view there is currently very limited knowledge about what additives 
to use for improving stability of the therapeutic compound (the cells), except for addition 
of osmotic agents such as NaCl. Several procedures during the production, transport, 
storage and even administration to the patient can potentially harm the cells and trigger 
cell death45,46. Therefore, stability, consistency and comparability tests are performed to 
ensure that product potency is preserved under different circumstances encountered from 
production up to bedside administration43. Many different cell assay analysis methods exist 
for cell viability determination. Nevertheless, the greatest challenge in CTP development is 
the inability to reliably characterize critical cell attributes. National Institute of Standards & 
Technology (NIST) has published an article on a number of strategies that could be used 
to ensure measurement confidence47. Techniques employed for cell counting and viability 
determination vary in the nature of the test sample (e.g., starting material, in-process sample 
and final drug product) as well as in the required performance of the test.  An assessment 
of viability without counting will be likely of little use and therefore a single method that 
provides both parameters will in most situations be the most efficient solution47.  
Methods to count cells mostly depend on the ability of the method to distinguish a cell 
from other particulates, such as visualization (e.g., microscopy), light scattering (e.g., flow 
cytometry) and electrical impedance. For measuring the concentration of viable cells, 
labeling with a fluorescent dye is normally required. Trypan blue48 (passes the membrane 
of dead cells) and propidium iodide (passes ruptured cell membranes and becomes 
fluorescent upon binding nucleic acid49) are frequently used dyes for this purpose. Two 
well-known cell viability assays are hemocytometry and flow cytometry. Hemocytometry 
is a very fast method to determine the total cell concentration and percent of (viable) cells 
in a sample that is spiked with a dye under a microscope48. In a flow cytometer single 
cells from a cell suspension pass through the designated fluorescence and light scattering 
detectors. A scatter plot of the scattering signal (which is related to the type and size of 
the cell) and fluorescence signal (representing the viability) is plotted, and with that the 
percentage of viable cells can be derived. Flow cytometry-based methods can be very 
accurate and reproducible; however, determination of the cell concentration is not easily 
attained. Therefore, the search for new techniques and methods for qualitative and 
quantitative analysis of CTP may contribute to improved quality control of this emerging 
group of pharmaceutical products. 
Aim and outline of this thesis
The aim of this thesis is to explore novel applications and capabilities of a number 
of particle analysis techniques to characterize complex injectable formulations, 
including (aggregated) protein solutions, protein-polyelectrolyte complexes, PLGA 
microspheres and cells. The outcome of our research should lead to (further) 
application of these tools for characterization of complex injectable formulations and 
therewith improve the quality of pharmaceutical products used in modern healthcare. 
The research described in Chapter 2 concerns an investigation of the cause of stirring induced 
protein aggregation, in order to unravel the mechanism behind this well-known mechanical 
source of particle formation. To this end, size-exclusion chromatography, nanoparticle 
tracking analysis and Micro-Flow Imaging (MFI; a flow imaging microscope) were used. 
In Chapter 3, the same combination of analytical techniques is utilized to study the kinetics 
of the formation and growth of protein-polyelectrolyte complexes driven by electrostatic 
interactions. 
In Chapter 4 and 5 novel applications of flow imaging microscopy techniques for the 
characterization of PLGA microspheres are introduced. The focus of Chapter 4 lies in 
investigating the ability of FlowCAM (a flow imaging microscope) to be used as a tool to 
analyze the sedimentation behavior of these particles, in order to deduce their porosity. 
In Chapter 5 MFI is used to measure the total volume of microspheres in a suspension 
with known microsphere concentration in order to determine the batch porosity of PLGA 
microspheres. 
In Chapter 6 MFI- and FlowCAM-based label-free methods are presented for counting and 
assessing the viability of B-lineage acute lymphatic leukemia cells. Chapter 7 summarizes 
the main findings and conclusions of the work described in this thesis. In addition, the future 
of particle analysis  techniques in the field of pharmaceutical formulation development is 
discussed. 
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Abstract
This study addressed the effect of contact sliding during stirring of a monoclonal antibody 
solution on protein aggregation, in particular in the nano- and micrometer size range An 
overhead stirring set-up was designed in which the presence and magnitude of the contact 
between the stir bar and the container could be manipulated. A solution of 0.1 mg/mL of a 
monoclonal antibody (IgG) in PBS was stirred at 300 rpm at room temperature. At different 
time points, samples were taken and analyzed by nanoparticle tracking analysis, flow 
imaging microscopy and size-exclusion chromatography. In contrast to non-contact stirred 
and unstirred samples, the contact stirred sample contained several-fold more particles and 
showed a significant loss of monomer. No increase in oligomer content was detected. The 
number of particles formed was proportional to the contact area and the magnitude of the 
normal pressure between the stir bar and the glass container. Extrinsic DCVJ fluorescence 
indicated a conformational change for contact stirred protein samples. Presence of 
polysorbate 20 inhibited the formation of micron sized aggregates. We suggest a model in 
which abrasion of the potentially destabilized, adsorbed protein leads to aggregation and 
renewal of the surface for adsorption of a fresh protein layer.
Introduction
Therapeutic proteins have gained a paramount place in modern pharmaceuticals, accounting 
for more than 70% of the total revenue generated by the ten best-selling pharmaceuticals1. 
The share of therapeutic proteins in the pharmaceuticals under development is also getting 
bigger while the probability of regulatory approval from entering clinical development is 
32% for therapeutic proteins versus 13% for small-molecule drugs 2,3. In this category of 
pharmaceuticals, monoclonal antibodies account for almost half of the sales 4. The benefits 
of therapeutic monoclonal antibodies have been proven to be of great value in many 
life-threatening diseases including cancer, inflammatory and immune diseases, such as 
rheumatoid arthritis5,6. 
Despite this important role of therapeutic proteins in pharmacotherapy, their marginal 
stability remains an important challenge in formulation, storage, shipping, and delivery of 
these drugs. Stability issues very often imply aggregation of proteins, which could lead to 
immunogenicity7,8 and/or reduced efficacy of the drug 9. Therefore, regulatory authorities 
have developed guidelines for quality control of protein drug formulations which often 
contain upper limits for the concentration of visible and sub-visible particles (including 
protein aggregates) present in parenteral drug products10-12. 
Many external factors that cause the aggregation of therapeutic proteins have been 
identified13,14. Among those, mechanical stresses in form of shaking and stirring of liquid 
protein formulations 15-21 have been shown to potentially induce considerable amounts of 
protein aggregates. These types of stress factors are encountered commonly at different 
stages from manufacturing process up to bedside administration to the patient. Recently, 
Kiese et al. showed that stirring of a liquid IgG1 formulation results in large numbers of micron 
sized aggregates, whilst the consequence of shaking was limited to formation of (high-
molecular-weight) oligomers and was dependent on presence of an air-filled headspace 
in a bottle 15. It was also shown that polysorbate 20 had a protective effect on antibody 
formulations against aggregation. The authors have listed several parameters, including 
shear, interfacial effects, and cavitation, that could potentially lead to severe aggregation of 
protein during stirring. Bee et al. ruled out the effect of high shear force on the aggregation 
of an antibody 22. There are studies that have addressed the effects of other parameters on 
protein aggregation, however, the exact underlying mechanism of stirring stress-induced 
aggregation is still not fully understood. 
In a typical stirring-stress study, stirring involves a constant contact sliding of the surface 
of a stir bar against the solid surface of a container. Such contact would disturb a critical 
solid-liquid interface that is a target for protein adsorption. Interestingly, however, to our 
knowledge the effect of the contact sliding of the solid surfaces, as present during the 
stirring, on aggregation of proteins has not been investigated. 
In this study, we addressed the effect of contact sliding during stirring of a liquid monoclonal 
antibody protein formulation on aggregation of the protein. For this purpose a stirring 
configuration has been designed in which the presence, magnitude, and normal pressure 
of the contact between the solid surfaces can be manipulated. The aggregation of the 
antibody was monitored by size-exclusion chromatography, nanoparticle tracking analysis, 
and flow imaging microscopy. Our results indicate that contact sliding-triggered abrasion of 
adsorbed protein is the key to the formation of micron sized aggregates induced by stirring.
Materials and Methods
Materials
Phosphate buffered saline (PBS; 8.2 g/L NaCl, 3.1 g/L Na2HPO4.12H2O, 0.3 g/L 
NaH2PO4.2H2O, pH 7.4) was obtained from Braun (B. Braun Melsungen AG, Germany) 
and filtered by using a 0.22-µm polyethersulfone-based syringe driven filter unit (Millex GP, 
Millipore, Carrigtwohill, Ireland). Polysorbate 20, sodium phosphate dibasic dihydrate, sodium 
phosphate monobasic dihydrate, sodium azide, sodium sulfate and 9-(2,2-dicyanovinyl) 
julolidine (DCVJ) were obtained from Sigma (Sigma-Aldrich, Steinheim, Germany). Ethanol 
was purchased from Biosolve (Biosolve B.V., Valkenswaard, The Netherlands). Ultrapure 
water (18.2 MΩ.cm) was dispensed by using a Purelab Ultra water purification system 
(ELGA LabWater, Marlow, UK). A monoclonal human IgG1 (IgG), formulated at 65 mg/mL 
in 10 mM sodium citrate buffer containing 5% sucrose at pH 6.0 as described before 23-25, 
was used as a model protein. This stock solution was diluted to a concentration of 
0.1 mg/mL IgG in PBS, either with or without 0.01% (w/v) polysorbate 20. In addition, 
a solution of 0.5 mg/mL IgG in PBS without polysorbate 20 was also prepared. Furthermore, 
a monoclonal human antibody of the IgG1 subclass (IgG-BI), kindly provided by Boehringer 
Ingelheim (Biberach, Germany), myoglobin (from equine skeletal muscle) and bovine 
serum albumin (BSA), both purchased from Sigma (Sigma-Aldrich, Steinheim, Germany), 
were used as model proteins in a small set of experiments.
Mechanical stress conditions
The stirring stress was generated at room temperature by magnetic stirring or an in-house 
designed overhead stirring system. For the magnetic stirring system a Teflon-coated stir bar 
with a diameter of 8 mm and a length of 40 mm, a flat-bottom crystallizing glass (diameter 
of 70 mm) (cat. no. 2131141; Duran; Schott, Mainz, Germany) and a magnetic stirrer (RCT 
basic IKAMAG, IKA-Werke GmbH, Staufen, Germany), operating at a constant rate of 300 
rpm, were used. The overhead stirring system (Figure 1) was used to study the effects of 
surface contact, contact area, and force generated by the stir bar on the glass surface. 
For this series of experiments a rod was used to fix an in-house designed stir bar made of 
polyether ether ketone. The shape and dimensions of this bar were similar to the one used 
with magnetic stirring experiments. The effect of surface contact was investigated by stirring 
80 mL of IgG solution at 300 rpm while the stir bar contact slid over the glass surface. A 
balance placed underneath the glass container was used to monitor the force applied by 
the stir bar (force calculated through multiplication of the displayed mass and gravitational 
force), which was in this case 5.88 N. Similarly, non-contact stirring was performed by 
stirring with 5 mm space between the stir bar and the surface of the glass container. As 
negative control an equal amount of IgG solution was left for 270 min unstirred in the same 
type of crystallizing glass at room temperature. An additional control consisted of stirring 
with contact sliding (or magnetic stirring) of protein free PBS. 
All the above-mentioned stirring conditions were applied for polysorbate-free IgG solutions. 
In addition, the contact sliding stirring experiments were performed with polysorbate-
containing IgG solutions. 
Figure 1: Scheme of the experimental set-up for the overhead stirring system used in 
this study. The rotor (A) turned the stir bar (B) with a rotation speed of 300 rpm, while the 
normal force (C) applied to the bottom of the glass container (D) during the contact mode 
was monitored by the balance (E). Stirring in the absence of any contact was performed by 
rotating the stir bar at a distance of ~5 mm from the bottom of the container. Bottom figure: 
the system with a reduced contact area by using a stir bar with cavities on its lower surface.
stirring with 5 mm space between the stir bar and the surface of the glass container. As 
negative control an equal amount of IgG solution was left for 270 min unstirred in the same 
type of crystallizing glass at room temperature. An additional control consisted of stirring with 
contact sliding (or magnetic stirring) of protein free PBS. All the above-mentioned stirring 
conditions were applied for polysorbate-free IgG solutions. In addition, the contact sliding 
stirring experiments were performed with polysorbate-containing IgG solutions. In order 
to investigate the effect of the contact area, a modified stir bar with the same dimensions, 
but half the contact area, was used while the normal force upon contact was reduced to 
2.94 N to keep the applied pressure the same. In addition, the stir bar with full contact 
Figure 2: Schematic overview of the sampling time points for each type of measurement 
performed in this study. The length of each rod indicates the approximate analysis time per 
sample, including sample pretreatment and handling.
In order to investigate whether the results are applicable to other antibodies and proteins, 
the contact and non-contact stirring together with the negative control experiments were 
also performed with three other protein solutions, namely 0.1 mg/mL BSA, 0.1 mg/mL 
IgG-BI and 0.5 mg/mL myoglobin, all in PBS. 
Size-exclusion chromatography
High pressure size-exclusion chromatography (SEC) was performed to quantify the amount 
of IgG monomer and oligomers in the unstressed and mechanically stressed samples. This 
was executed on an Agilent 1200 chromatography system (Agilent Technologies, Palo Alto, 
California) combined with a Wyatt Eclipse (Wyatt Technology Europe GmbH, Dernbach, 
Germany). A Yarra 3 µm SEC-2000 column (300 × 7.8 mm) coupled with a Yarra Security 
Guard precolumn (Phenomenex, Torrance, CA, USA) was used. One mL of the samples 
was centrifuged (18,000 x g for 15 minutes) to remove large particles and 100 µL of the 
supernatants were injected, while separation was performed at a flow rate of 0.5 mL/min. 
The mobile phase consisted of 100 mM sodium phosphate, 100 mM sodium sulfate, and 
0.05 % w/v sodium azide at pH 7.2. Ultraviolet absorption detection was performed at 280 
nm. In order to calculate the monomer decrease after stress, the areas under the curve 
(AUC) of the UV signal of the monomer peak were used. Standard curves were obtained 
by using pure IgG samples of known concentrations.
Dynamic light scattering
DLS measurements were performed with a Malvern Zetasizer Nano ZS (Malvern, 
Herrenberg, Germany). For the collection and analysis of data the Dispersion Technology 
area was used with a reduced normal force of 1.96 N, to study the effect of pressure. The 
samples were takenat different time points according to the scheme depicted in Figure 2 
and immediately analyzed. 
Software version 7.03 from Malvern was used. Five hundred µL of each sample was 
measured in single-use polystyrene half-micro cuvettes (Fischer Emergo, Landsmeer, The 
Netherlands) with a path length of 10 mm. 
Nanoparticle tracking analysis
Nanoparticle tracking analysis (NTA) was performed with a NanoSight LM20 (NanoSight 
Ltd., Amesbury, United Kingdom) equipped with a 640 nm laser and operating at an angle 
of 173° with respect to the flow cell (100 x 80 x 10 µm). Samples were injected into the 
chamber by an automatic pump (Harvard Apparatus, catalog no. 98-4362, Holliston, USA) 
using a sterile 1-mL syringe (BD Discardit II, Franklin Lakes, New Jersey). The settings 
were optimized for NTA analysis of solutions containing high quantities of micrometer sized 
particles, based on a previous study26. For each sample a 90 s video was captured with the 
shutter set at 1495 and the gain at 400. Videos were analyzed by using the NTA 2.0 Build 
127 software. The following settings were used for tracking of the particles: background 
extract on; brightness 0; gain 1.00; blur size 3x3; detection threshold 10, viscosity equal 
to that of water. All other parameters were set to the automatic adjustment mode. Only 
particles in the 100 – 800 nm size range were included in the analysis. 
Flow imaging microscopy
A Micro-Flow Imaging (MFI) system (MFI5200, ProteinSimple, Santa Clara, USA), equipped 
with a silane coated flow cell (1.41 x 1.76 x 0.1 mm) and controlled by the MFI View System 
Software (MVSS) version 2, was used for flow imaging microscopy analysis. The system 
was flushed with 4 mL purified water at 6 mL/min prior to each measurement. The flow cell 
cleanliness was checked visually between measurements. The background was zeroed 
by flowing PBS and performing the ‘optimize illumination’ procedure. Samples of 0.5 mL 
with a pre-run volume of 0.2 mL were analyzed at a flow rate of 0.17 mL/min and a fixed 
camera shot rate of 22 flashes per second. The data recorded by the MVSS was analyzed 
with MFI View Analysis Suite (MVAS) version 1.2. For each sample, stuck, edge, and 
slow-moving particles were removed by the software before data analysis. The equivalent 
circular diameter (ECD), which is the diameter of a circle that has an area equal to that of 
the particle imaged by MFI, was calculated and presented as a measure of the particle size 
(1-100 µm).
Circular dichroism
Far-UV circular dichroism (CD) was used to study the secondary structure of the protein before 
and after stirring. The measurements were performed with a Jasco J-815 CD spectrometer 
in combination with a Jasco PTC- 423S temperature controller (Jasco International, 
Tokyo, Japan) at 25◦C. The samples were measured in quartz cuvettes (Hellma GmbH, 
Muellheim, Germany) with a path length of 1 mm. Circular dichroism spectra were collected 
in a continuous scanning mode from 200 to 250 nm. The measurements were performed at 
a scanning speed of 50 nm/min, a response time of 2 s, a bandwidth of 1 nm, a sensitivity 
of 100 m◦, steps of 0.5 nm, and an accumulation of 6 scans. Using the Spectra Analysis 
Software (version 1.53.04, Jasco), the spectra were background corrected by subtracting 
the spectrum of the buffer. Data were calculated to mean residue ellipticity according to 
previously described equations 25 by using a mean amino acid residue weight of 113.
Intrinsic and extrinsic fluorescence spectroscopy
Intrinsic and extrinsic fluorescence measurements were conducted with an FS920 
fluorescence spectrometer (Edinburgh Instruments, Edinburgh, UK) at 25 °C using quartz 
cuvettes with a path length of 10 mm. For intrinsic fluorescence measurements, tryptophan 
was selectively excited at 295 nm. Changes in emission spectra will reveal alterations in 
the tertiary structure of IgG27. The emission spectra were recorded from 300 to 500 nm
using emission and excitation slits of 3 nm, a dwell time of 0.5 s, steps of 0.5 nm, and 
a cumulative addition of three scans for each spectrum. All spectra were corrected by 
subtracting the emission spectrum of the buffer measured under the same conditions 
as the samples. For extrinsic fluorescence spectroscopy DCVJ was used, which allows 
detection of changes in protein structure28, also in polysorbate-containing solutions29. For 
this part of the study an additional stress condition (thermal stress) was incorporated as a 
positive control, in order to get a general idea on the relative extent of the conformational 
changes introduced by stirring stress29. To induce thermal stress, 1.5 mL of polysorbate-
containing and polysorbate-free IgG solutions were heated for 10 minutes at 75°C in a 
1.5-ml reaction tubes (Eppendorf, Hamburg, Germany) using a thermomixer (Eppendorf, 
Hamburg, Germany). The aggregation of antibodies under these conditions was thoroughly 
investigated previously and is reported elsewhere23,25,29. The used temperature was 
aggregation onset temperature of the IgG and no visible precipitation was observed after 
this treatment. For each tested condition 50 μL of a 100 μM DCVJ stock solution was added 
to 950 μL protein solution to achieve a dye concentration of 5 μM. IgG/DCVJ mixtures were 
measured within 30 min after dye addition. DCVJ was excited at 452 nm and an emission 
scan from 470 to 650 nm was performed. The measurements were performed with slits of 
3 nm, steps of 1 nm and a dwell time of 0.5 second. 
Results
Protein aggregation induced by magnetic stirring   
Figure 3: Effect of magnetic stirring on protein aggregation. Aggregation was monitored 
as function of time for magnetically stirred IgG solution (contact stirring) with and without 
0.01% polysorbate 20 (PS20), unstirred IgG solution, and stirred PBS. Plots show the total 
concentrations of A) nanometer sized particles as measured by NTA and B) micron sized 
particles as measured by MFI; C) nanometer particle size distribution of contact stirred 
solution as measured by NTA and D) micrometer particle size distribution of contact stirred 
solution as measured by MFI; E) percentages of monomeric IgG still in solution as measured 
by SEC. All the graphs show the average and standard deviation of triplicate experiments, 
except for panel C and D, which show the results of one of the replicates.
Magnetic stirring of IgG solution for 90 min resulted in the formation of large numbers of 
particles in the size range of about 100 nm to 3 μm, as detected by NTA and MFI (Figure 
3A-B). In particular, the formation of up to 135,000 micron sized particles per mL with a 
consistent average size of 1.60 µm and an irregular shape (Figure 4) was observed by MFI. 
Figure 4: Examples of MFI images of particles detected in magnetically stirred (after 90 min), 
non-contact stirred (after 270 min) and contact stirred (after 270 min and 5.88 N pressure) 
IgG solutions.
The number of particles increased over time and stirring led to generation of more nanometer- 
and micron sized particles continuously (Figure 3C-D). SEC analysis revealed a decrease 
of more than 5 % in monomer content after 90 min, but no increase in the amount of (high 
molecular weight) oligomers, as shown in Figure 3E and 5. DLS measurements revealed an 
increase in the Z-average diameter and PDI already in the first measurement after the start 
of magnetic stirring (results not shown). Since DLS analysis was not sufficiently distinctive 
for samples containing substantial numbers of micron sized particles, it was not used for 
follow-up experiments. 
Figure 5: Representative SEC chromatograms of unstirred and magnetically stirred IgG 
solution. The insert shows a zoom-in view of the monomer and oligomer peak.  
Unstirred IgG solution and stirred placebo solution (PBS) did not show any particle formation. 
Stirred IgG solution containing 0.01% polysorbate 20 did not exhibit any increase in the 
number of micron sized particles (MFI, Figure 3B) or monomer loss (SEC, Figure 3E), but 
did show an increase over time in nanometer sized particles (NTA, Figure 3A), albeit to a 
lesser extent than the stirred polysorbate-free IgG solution.   
Effect of contact sliding on protein aggregation and micron sized particle formation
In this part of the study we employed an overhead stirring system, where the contact of the 
stir bar with the container surface could be manipulated (Figure 1). NTA and MFI analysis 
indicated that stirring with contact sliding of polysorbate-free IgG solution created high 
numbers of particles. At this stirring condition the average total nanometer sized particle 
concentration increased from 0.1 x 108 per mL at t = 0 to 1.8 x 108 per mL after 90 minutes, 
as observed by NTA (Figure 6A and C). Moreover, MFI showed an increase in the average 
total micron sized particle concentration from about 1000 (t = 0) up to 1.7 x 106 per mL 
with an average particle size of 1.78 μm after 270 min of stirring (Figure 6B and D), while 
SEC showed a 10% decrease of IgG monomer content in solution (Figure 6E). In contrast, 
non-contact stirred protein solution showed only a minor increase in both nanometer- and 
micron sized particle counts, without a significant decrease in monomer content. For both 
contact and non-contact stirred samples, particles with a size above 5 µm had irregular 
shapes (Figure 4). 
Figure 6: Effect of contact stirring and non-contact stirring on protein aggregation. 
Aggregation was monitored as function of time for IgG solution with and without 0.01% 
polysorbate 20 (PS20) stirred with contact sliding of the stir bar over the glass surface 
(pressure 5.88 N), IgG solution without polysorbate 20 stirred without contacting the glass, 
unstirred IgG solution, and stirred PBS. Plots show the total concentration of A) nanometer 
sized particles of contact stirred solution as measured by NTA and B) micron sized particles 
of contact stirred solution as measured by MFI; C) nanometer particle size distribution 
as measured by NTA and D) micrometer particle size distribution as measured by MFI; E) 
percentages of monomeric IgG still in solution as measured by SEC. All the graphs show the 
average and standard deviation of triplicate experiments, except for panel C and D, which 
show the results of one of the replicates.
The results for unstirred IgG, contact stirred PBS and contact stirred polysorbate-containing 
IgG solution were very similar to those obtained for the corresponding samples in the 
magnetic stirring study (cf. Figure 3 and 6). Again, unstirred protein samples and stirred 
PBS did not show any significant increase in nanometer- and micron sized particle counts, 
and no IgG monomer loss was found in unstirred IgG solution. In the contact stirred IgG 
solution containing 0.01% polysorbate 20 the generation of micron sized particles was 
substantially inhibited and hardly any decrease in monomer concentration was seen, 
whereas the number of particles in the nanometer range was slightly increased. 
When the IgG concentration in the solution was increased to 0.5 mg/mL and contact stirring 
was applied, the micron sized particle concentration reached almost 3.0 x 106 per mL after 
270 minutes (Figure 7), with an average size of 2.98 μm. The monomer content decreased 
with 4.9% after 270 minutes of contact stirring. Because of the high number of micron sized 
particles, which interfered with the NTA measurements, the concentration of nanometer 
sized particles could not be reliably assessed.      
Figure 7: Contact stirring of 0.5 mg/mL IgG solution. The decrease in IgG monomer 
concentration is shown in black circles and is depicted on the left y-axis. The green triangles 
show the total number of micrometer-sized particles, with the values depicted on the right 
y-axis. All the graphs show the average and standard deviation of triplicate experiments.
Effect of contact area and normal pressure of the contact sliding on micron sized particle 
formation
Figure 8: Effect of contact area and normal pressure on stirring-induced protein aggregation. 
Aggregation was monitored as function of time for IgG solution stirred with the full contact 
area, IgG solution stirred with reduced contact area, IgG solution stirred with reduced 
pressure, and unstirred IgG solution. Plots show the total concentration of A) nanometer 
sized particles as measured by NTA and B) micron sized particles as measured by MFI; and 
C) percentages of monomeric IgG still in solution as measured by SEC. All the graphs show 
the average and standard deviation of triplicate experiments.
In the first part of this stirring experiment, the effect of the contact area between the stir 
bar and the bottom of the container on the magnitude of aggregation was investigated. 
As shown by the number of nanometer- and micron sized particles per mL (Figure 8A and 
B), stirring for 90 min with a reduced contact area generated fewer particles compared to 
full contact area (4.4 x 105 vs. 1.7 x 106 micron sized particles per mL, respectively). The 
monomer content was significantly decreased only in the stirring set-up with full contact 
sliding area (Figure 8C). 
The second part of this experiment concerned the effect of normal pressure. The 
concentration of both nanometer- and micron sized particles after stirring for 90 min with 
reduced normal pressure (1.96 N) was less than that upon stirring with full pressure 
(5.88 N), while monomer losses in SEC of  6%  (reduced pressure) and 7% (full pressure) 
were comparable (p = 0.42, Student’s t-test). 
Figure 9: Steady-state fluorescence spectra of DCVJ  spiked into IgG solution stirred with 
contact sliding of the bar over the glass surface (black), IgG solution without contacting the 
glass (red), unstirred IgG solution (blue), and heat stressed IgG (brown) in A) absence and B) 
presence of 0.01% polysorbate 20.
The secondary and tertiary structure of IgG in untreated, contact sliding, and non-
contact stirred IgG solutions was studied by using far-UV CD and intrinsic fluorescence 
spectroscopy, respectively. These experiments did not reveal any alteration in secondary 
and tertiary conformation under any of the stirring conditions (data not shown). In contrast, 
extrinsic fluorescence measurements with DCVJ showed a slight increase in fluorescence 
intensity in the spectrum of the contact stirred polysorbate-free IgG solution as compared 
to unstirred and non-contact stirred IgG solutions (Figure 9A), although less than for the 
heat stressed control. Interestingly, the polysorbate-containing IgG formulation exposed to 
contact stirring showed a similar spectral intensity as the unstirred and non-contact stirred 
control samples (Figure 9B), indicating that polysorbate indirectly inhibited the induction of 
conformational changes during contact stirring.
Stirring of other protein solutions
The stirring experiments with and without contact sliding together with the unstirred control 
experiment were also performed with another monoclonal IgG antibody, BSA and myoglobin. 
As shown in Table 1, contact stirring of all the three protein solutions led to significant 
increases in the numbers of both nanometer- and micron sized particles, whereas this 
was not the case for the corresponding unstirred and non-contact stirred protein solutions. 
However, according to SEC analysis only IgG-BI solution showed a significant monomer 
content decrease after 270 minutes of contact stirring, while in none of the samples 
oligomers were detected (results not shown).   
Table 1: Summary of the effect of non-contact stirring and contact stirring on aggregation 
of 3 other proteins. 
* Significant increase/decrease compared to unstirred and non-contact stirred sample 
(P < 0.05)
Discussion
Stirring stress is commonly applied in forced degradation studies of protein pharmaceuticals30. 
This study is the first one comparing contact stirring versus non-contact stirring with respect 
to induction of protein aggregation. The overall results clearly show that contact sliding of 
the stir bar over the surface of the container plays a key role in stirring-induced protein 
aggregation and indicate that shear alone does not induce aggregation, in line with a 
study by Bee et al. 22. Corroborating previous studies on stirring-induced aggregation15,31-33, 
magnetic stirring led to a significant increase in the number of nanometer- and micron sized 
particles. The imaged particles by MFI indicated that a large quantity of the particles were 
a few micrometers in size. No increase in number of micron sized particles was observed 
when only the buffer solution was magnetically stirred, indicating that particles formed in 
magnetically stirred IgG solution were proteinaceous. This increase in number of particles 
was accompanied with a clear decrease in the protein monomer content in absence of 
oligomers, suggesting a severe and rapid particle formation due to stirring. A five-fold 
higher IgG concentration resulted in not only larger numbers and sizes of micron sized 
particles, but also appearance of visible particles. These events were accompanied by a 
faster relative monomer content decrease compared to the experiments done at an IgG 
concentration of 0.1 mg/mL. The underlying reason for this faster decrease in monomer 
content could be two-fold: a) the more abundant the monomer in solution becomes, the 
faster the solid surface gets covered with protein and b) the presence of a higher protein 
concentration would facilitate any potential aggregation via monomer addition. 
Based on the method described by Barnard and co-workers34, where it is assumed that 
particles are spherical and consist of 75% protein and 25% water, after 90 min of stirring 
the amount of protein in the nanometer- and micron sized particle fractions was calculated 
to be less than 0.01% and about 1.6%, respectively, of the total protein mass. This is less 
than what would be expected, considering the monomer loss observed in SEC (ca. 5%). In 
contrast, when using the overhead system in the contact mode the amount of protein in the 
particles generated in the contact stirred IgG solution (stirring time 270 min) was estimated 
to be about 19.4% of total protein, whereas the monomer loss in SEC was about 10%, i.e., 
in this case the apparent total recovery was above 100%.  
These discrepancies may be explained by the inaccuracy of the assumptions (spherical 
shape and 75% protein content in a particle) made in this method. Kalonia et al. proposed 
a refinement of particle volume calculation based on the morphological parameters (aspect 
ratio and circularity) of the particles provided by the MFI35. Even so, when a majority of the 
micron sized particles is smaller than 5 μm, the resolution of the images is not sufficient to 
reliably derive the morphological parameters. From an analytical point of view a few other 
arguments can contribute to the error as well. One of those is the inability of both NTA 
and MFI to accurately size heterogeneous protein particles with a size around 1 μm, i.e., 
at about the upper and lower size limit, respectively, of the instrument. In addition, all the 
methods used in this study are based on different analytical principles, which could lead to 
some level of inconsistency between orthogonal techniques36. 
In order to study the effects of the contact between the stir bar and the container, an 
overhead system that allows stirring in both contact and non-contact modes was used. 
Stirring without a contact between the stir bar and the glass container did not lead to the 
formation of large amounts of aggregates. In contrast, stirring in contact mode led to the 
formation of millions of micron sized particles along with substantial loss of IgG monomer in 
solution, similar to the observations in magnetic stirring. A DCVJ fluorescence assay, which 
probes the microenvironment of protein molecules28,37, indicated some conformational 
changes in the protein sample that was contact-stirred. Intrinsic fluorescence and CD were 
not sensitive enough to pick up this change in protein conformation. Likely, only a small 
fraction of the total protein amount are structurally altered, which can be sensitively picked 
up by the fluorescent dye assay but not by the other spectroscopic methods which mainly 
probe the bulk of unaffected, native monomeric protein. 
Based on the collective data, we suggest the following model for the mechanism of 
aggregation induced by magnetic stirring of protein solutions, as summarized in Figure 10. 
After attachment to a solid surface, proteins often undergo conformational changes38,39. An 
adsorbed protein molecule with a perturbed state can facilitate adsorption of more protein 
molecules, leading to aggregation on the surface. Contact sliding of the bar abrades the 
formed protein layer (consisting of perturbed monomers and/or aggregates) off the surface, 
releasing the perturbed protein or protein aggregate into the bulk, which may be followed 
by further aggregation in solution, eventually leading to the formation of nanometer- and 
micron sized aggregates. Subsequent to the removal of the adsorbed protein layer, the 
cycle of protein adsorption starts again and abrasion of the new layer is repeated by sliding 
of the bar on the glass surface. This also explains why (contact) stirring stress in general is 
harsher than shaking stress15,33. 
In line with the proposed aggregation mechanism, the addition of polysorbate 20 had a 
clear inhibitory effect on IgG aggregation and conformational changes in contact-stirred 
samples. Several studies have indicated that the major mechanism of polysorbates in 
stabilizing protein involves the preferential adsorption of the surfactant at the interfaces40,41. 
In our system, the presence of polysorbate 20 in the IgG formulation is expected to greatly 
reduce the adsorption of the protein to the stir bar and the container surface, and therewith 
hampers the process of stirring-induced structural changes in the protein and subsequent 
aggregation. It has to be realized, however, that the presence of polysorbate 20 did not 
totally avoid the formation of nanometer sized particles during contact stirring (Figure 3A 
and 6A), whereas the polysorbate-containing IgG solution that was non-contact stirred 
showed no increase in nanometer sized particles at all. This might indicate that in the 
contact stirred polysorbate-containing solution aggregation may be happening but is greatly 
delayed. So, avoiding contact sliding during stirring and adding a surfactant will have a 
synergetic benefit in reduction of stirring-induced protein aggregation. 
It should be noted that adsorption of proteins is a known phenomenon for most engineering 
materials, unless there are measures taken to prevent or reduce the adsorption. In a small 
experiment with a Coomassie blue staining procedure we showed that IgG indeed adsorbed 
to solid surfaces of glass and stir bar used in this study; we also observed that the adsorption 
was inhibited to a great extent when polysorbate 20 was present (see Supporting Information 
for details).  In addition, we have studied the stirring induced protein aggregation also with 
a stirring system using a glass stir bar. These conditions led to formation of particles and 
loss of monomer as well. However, the glass bar had a different shape and size compared 
to the others used in this study and therefore the results were not included. 
The stronger beneficial effect of polysorbate 20, compared to avoidance of surface contact, 
can be explained by the fact that surfactants reduce the disposition of protein at the air-
water interface too. Stirring, either with or without contact sliding of the stir bar, induces 
continuous refreshment of the air-water interface 42. Just as the solid-liquid interface, 
the air-water interface is a source of adsorption, structural changes and subsequent 
aggregation of the protein adsorbed to this interface, as has been observed in shaking 
stress studies 15,42,43. At this stage, it is worth noting that the friction of the two solid surfaces 
can create a local temperature increase and therefore the effect of this parameter on the 
protein aggregation cannot be ruled out. However, our data shows that contact stirring of 
polysorbate 20 containing IgG solutions did not cause (considerable) protein aggregation, 
while the local heat creation would occur under these conditions as well.
Figure 10: Schematic representation of the suggested mechanism of stirring-induced 
protein aggregation. The left part (framed in blue) depicts the process of protein adsorption 
onto solid surfaces with potential perturbation of the native structure of the protein upon 
adsorption. This process is followed by aggregation at the surface and in the bulk (framed 
in red). Contact sliding results in abrasion of the adsorbed protein layer, leading to renewal 
of the surface for adsorption of a fresh protein layer. Addition of surfactants, such as 
polysorbate 20, and avoidance of contact stirring will inhibit the steps shown as blue and 
red arrows, respectively.
In order to further validate the model proposed in Figure 10, effects of the pressure 
between the stir bar and the container and contact area of the two solid surfaces on protein 
aggregation were studied. The extent of aggregation was shown to be influenced by 
adjusting the contacting area or reducing the pressure applied by the stir bar on the glass 
surface. Compared to stirring with normal pressure, the number of micron sized particles 
was less when the pressure between the stir bar and the bottom of the container was 
reduced, but with equal extent of monomer loss. Even less micron sized particles were 
found when the contact area was reduced, with no monomer loss over the studied time 
range. Reduction in normal pressure will directly affect the shear force applied on the glass 
surface. This in turn reduces the effective detachment of perturbed protein (layer) in the 
bulk solution. Another plausible explanation holds its origin in the flatness of the interacting 
surfaces. A smooth surface will still have ‘hills’ and ‘valleys’, even if lots of efforts have been 
made to get it as flat as possible. Together with plastic or elastic properties of a certain 
surface (e.g., a stirring bar or a container surface), the pressure can have a significant 
effect on the effective contact area 44, the poor control of which in general may have a 
negative impact on the reproducibility of stirring-stress studies. 
In our study we have shown that the phenomenon of contact sliding-induced protein 
aggregation holds true for another different antibody and two other model proteins as well. 
Although not all of the tested proteins showed a significant loss of monomer content, still a 
considerable increase in particle concentration was observed for each of them, suggesting 
that the phenomenon observed is broadly applicable to proteins in general. 
Prevention of protein aggregation from mechanical stress can be best achieved by adding 
surfactants and avoiding contact sliding of a stirring element and the inner surfaces of the 
container. The potential effects of contact sliding and abrasion are applicable to several 
systems other than stirring. For instance, Peters et al. showed that an increase in the 
aspiration and dispensing frequency during compounding of highly concentrated therapeutic 
protein solutions leads to enhanced protein aggregation45. In a different study, Colombié et 
al. 46 showed that stirring-induced aggregation leads to irreversible inactivation of lysozyme. 
This may have been caused by aggregation, which was unfortunately not addressed in this 
particular report. The same group investigated the effect of the glass-liquid interface size on 
lysozyme activity by introducing glass (micro)spheres before turbine-assisted stirring was 
started 31. The effect of sliding of the particles over each other and over the surface of the 
container may have played a significant role in the reduced lysozyme activity observed. In 
a more recent study of Mehta and coworkers 47 showed that repeated rupture of a layer of 
silicone oil overlaid on the surface of aqueous solutions of monoclonal antibody resulted in 
the formation of nanometer- and micron sized particles and substantial losses of monomer. 
This stress method is from a mechanistic point of view very similar to the one investigated 
in our work, and the two studies indicate that release or abrasion of (perturbed) monomers 
and/or aggregates adsorbed at either oil-water or solid-water interface leads to formation 
of proteinaceous particles in the bulk. Therefore, it is of great importance that the role 
of contact sliding between the solid surfaces in protein aggregation is recognized and 
taken into account when designing manufacture, formulation, and handling protocols for 
therapeutic proteins, as well as when setting up stirring stress studies.
Conclusion
Mechanical stress is one of the reasons that proteins aggregate during different stages of 
manufacturing and practical use in clinical settings. The data presented herein indicate that 
for stirring stress, contact sliding of the stir bar over the surface of the container plays a 
critical role in induction of protein aggregation. Our data suggests that abrasion of proteins 
adsorbed on solid surfaces leads to progressive protein particle formation in bulk solution, 
which can be best inhibited by avoiding contact of the stirring device with the container 
surface and adding a surfactant. 
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Supporting information
Visual appearance of the containers and stir bar after stirring and staining procedure. In 
brief, 80 mL PBS or protein solution was stirred at 300 rpm for 30 min. The solutions were 
discarded, and container and stir bar were rinsed thoroughly with PBS. Subsequently, 
80 mL 0.2% (w/w) Coomassie blue R-250 in 10% acetic acid was added and the samples 
were incubated for 30 min. The dye solution was removed, the glass and stir bar were 
extensively rinsed with 10% acetic acid.
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Abstract
The purpose of this study was to investigate the formation and growth kinetics of complexes 
between proteins and oppositely charged polyelectrolytes. Equal volumes of IgG and 
dextran sulfate (DS) solutions, 0.01 mg/ml each in 10 mM phosphate, pH 6.2, were mixed. 
At different time points, samples were taken and analyzed by nanoparticle tracking analysis 
(NTA), Micro-Flow Imaging (MFI) and size-exclusion chromatography (SEC). SEC showed 
a huge drop in monomer content (approximately 85%) already 2 minutes after mixing, 
while a very high nanoparticle (size up to 500 nm) concentration (ca. 9x108/mL) was 
detected by NTA. The nanoparticle concentration gradually decreased over time, while 
the average particle size increased. After a lag time of about 1.5 h, a steady increase in 
microparticles was measured by MFI. The microparticle concentration kept increasing up 
to about 1.5x106/mL until it started to slightly decrease after 10 h. The average size of the 
microparticles remained in the low-μm range (1-2 μm) with a slight increase and broadening 
of the size distribution in time. The experimental data could be fitted with Smoluchowski’s 
perikinetic coagulation model, which was validated by studying particle growth kinetics in 
IgG:DS mixtures of different concentrations. In conclusion, the combination of NTA and MFI 
provided novel insight into the kinetics and mechanism of protein-polyelectrolyte complex 
formation. 
Introduction
The interaction between proteins and polyelectrolytes has been receiving increasing 
attention in pharmaceutical sciences because of the growing importance of protein drugs1. 
The latter is mainly related to their specificity and the lack of toxic metabolites, resulting 
in considerably less interference with untargeted biological processes and, hence, less 
adverse effects and increased clinical efficiency2. Successfully developing protein drugs, 
however, requires the availability of highly pure protein batches as well as suitable 
formulations that guarantee the physical and chemical stability of the protein3-5 until its 
delivery at the target site. 
Polyelectrolytes are a major group of the macromolecules that have shown to offer 
advantages in purification6,7, stabilization8 and delivery of therapeutic proteins9,10. 
Polyelectrolytes are suitable as component of protein delivery systems because they can 
be selected with specific hydrophilicity, versatile charge properties, biodegradability, natural 
origin, and roles in preventing aggregation and denaturation of proteins11-14. Moreover, 
polyelectrolytes have been used to increase the amount of protein loaded onto the surface 
of solid microneedles and microparticles via layer-by-layer deposition of oppositely charged 
proteins and polyelectrolytes15,16. Furthermore, polyelectrolyte-mediated precipitation 
methods have been used in protein purification processes17 to decrease the number of 
isolation steps at a low cost. This approach is considered to be more selective than the use 
of other precipitants, such as ammonium sulfate or organic solvents18. In addition, another 
advantage of polyelectrolyte-assisted precipitation along with protein co-precipitation 
techniques19 is that these methods do not require organic solvents that could be harmful 
to the protein as well as the environment. The molecular interaction involves electrostatic 
interactions between charged surfaces of the protein and oppositely charged groups of 
the polyelectrolyte20. The onset of complexation depends on several parameters, such as 
pH, ionic strength, protein/polyelectrolyte ratio and physico-chemical characteristics of the 
protein and the polyelectrolyte (e.g., charge, size)21,22. These interactions create insoluble 
complexes, which then aggregate further to form larger particles that will eventually 
precipitate from the solution23. The process of particle growth depends not only on the 
nature of the particles, but also on external factors, such as temperature, stirring and 
sedimentation24. 
A great challenge in the direct assessment of protein-polyelectrolyte interactions has been 
the lack of techniques that are able to simultaneously detect, characterize and quantify 
(sub)visible particles that form upon complexation of protein and polyelectrolyte. Emerging 
particle analysis techniques25,26, however, may provide reliable ways to monitor protein-
polyelectrolyte complex formation and growth. In the nanometer range, nanoparticle tracking 
analysis (NTA) is a valuable technique that counts and sizes particles in a suspension. In 
the flow-cell of NTA, the particles scatter a beam of laser light, which is detected through 
a microscope and recorded into a video exhibiting the movement of particles in the 
suspension. The displacement of individual particles, or the Brownian motion, in a plane 
is tracked in time to deduce the individual particle size27-30. In the micrometer size range, 
flow imaging microscopy techniques, such as, Micro-Flow Imaging (MFI), are currently 
gaining ground as established methods for micron-size particle sizing and counting31-34. 
The principle of detection is based on the change in the light intensity passing through a 
particle compared to the background. Based on the captured images the particle size and 
count are derived. The same images can be used to assess several morphological aspects 
of individual particles, like aspect ratio and transparency.  The aim of this study was to 
develop a method based on the combination of NTA and MFI to monitor and characterize 
the process of particle formation and growth during protein-polyelectrolyte complexation, 
assisted by size-exclusion chromatography (SEC) to quantify the amount of unbound protein 
monomer. A monoclonal antibody was used as a model protein and dextran sulfate as a 
model polyelectrolyte. The experimental data for a few different experimental conditions 
were fitted with Smoluchowski’s perikinetic coagulation model35,36.
Materials and Methods
Materials
Dextran sulfate (from Leuconostoc spp., Mw = 5000), sodium phosphate dibasic dihydrate, 
sodium phosphate monobasic dihydrate, sodium azide and sodium sulfate (pKa < 2) were 
obtained from Sigma (Sigma-Aldrich, Steinheim, Germany). Ultrapure water (18.2 MΩ.cm) 
was dispensed by using a Purelab Ultra water purification system (ELGA LabWater, 
Marlow, UK). A monoclonal human IgG1 subclass (IgG; pI = 8.4), formulated at 65 mg/ml 
in 10 mM sodium citrate buffer containing 5% sucrose at pH 6.0, described before29,37,38, 
was  used as a model protein. Stock solutions of 0.01 mg/ml of IgG in aqueous solution of 
10 mM phosphate buffer, pH 6.2 (filtered by using a 0.22-µm polyethersulfone-based 
syringe driven filter unit (Millex GP, Millipore, Ireland)), was prepared. The same buffer 
was used to prepare stock solutions of 0.01 mg/ml dextran sulfate. In preliminary studies 
we found that a low buffer concentration and a pH value lower than 7 are beneficial for the 
formation of IgG-dextran sulfate complexes. Addition of the protein or polyelectrolyte had 
no effect on the pH of 6.2. 
Mixing, incubation and sampling procedure
A volume of 13 mL of the IgG stock solution was poured into a graduated glass cylinder 
(Duran®, Hirschmann, Eberstadt, Germany), with an inner diameter of 1.4 cm and a height 
of 14.9 cm. 13 mL of the dextran sulfate stock solution was added to the IgG solution. 
Subsequently, the IgG/dextran sulfate mixture was homogenized by gentle pipetting up and 
down 15 times, and then incubated for a period of 14 hours. In order to avoid unwanted 
movements and temperature fluctuations (as these might affect the kinetics of the particle 
growth), the glass container was kept on a sturdy bench where the analytical instruments 
were located. The first sample was taken immediately after mixing. The sampling was 
continued for 840 min after preparation according to the scheme shown in Figure 1. 
Figure 1: Schematic overview of the sampling time points for each type of measurement 
performed in this study. The length of each rod indicates the approximate analysis time per 
sample, including sample pretreatment and handling. 
Samples were directly used for the different analyses, unless otherwise stated.  The 
experiment was performed twice. During the experiment the room temperature in the lab 
was monitored (23 ± 0.8 °C). In order to prepare samples for quantification of the free 
protein monomer content, 1 mL of the sample was centrifuged in a 1.5 mL Eppendorf tube 
at 18,000 ×g for 15 minutes. A hundred µL from the top part of the liquid was taken and 
immediately used for measurement of the monomer content by using SEC.  The supernatant 
was analyzed by NTA to confirm that it was free of particles (results not shown). 
In order to check the applicability of the method to other formulations and to validate whether 
Smoluchowski’s perikinetic coagulation model (see below) describes the particle formation 
process, additional mixing experiments were performed with two different concentrations 
of IgG and dextran sulfate in the starting materials, namely 0.005 and 0.02 mg/mL (instead 
of 0.01 mg/mL). The experimental procedure was kept the same, except that the particle 
formation process was monitored for only 270 min. 
Size-exclusion chromatography
High pressure size-exclusion chromatography (SEC) was performed to quantify the amount 
of free IgG monomer in the solution in absence and presence of dextran sulfate. This was 
executed on an Agilent 1200 chromatography system (Agilent Technologies, Palo Alto, 
California) combined with a Wyatt Eclipse (Wyatt Technology Europe GmbH, Dernbach, 
Germany). A Yarra 3 µm SEC-2000 column (300 × 7.8 mm) coupled with a Yarra Security 
Guard precolumn (Phenomenex, Torrance, CA, USA) was used. Centrifuged 
(18,000 x g for 15 minutes) samples (100 µL) were injected and separation was performed 
at a flow rate of 0.5 mL/min. The mobile phase consisted of 100 mM sodium phosphate, 
100 mM sodium sulfate, and 0.05 % w/v sodium azide at pH 7.2. Ultraviolet absorption 
detection was performed at 280 nm. In order to calculate the monomer decrease after 
complexation, the areas under the curve (AUC) of the UV signal were used. 
Nanoparticle tracking analysis
NTA was performed at room temperature (23 ± 0.5°C) with a NanoSight LM20 (NanoSight 
Ltd., Amesbury, United Kingdom) equipped with a 640 nm laser and operating at an angle 
of 173° with respect to the flow cell (100 x 80 x 10 µm). Samples were taken from the 
mixture vessel by using a sterile 1 mL syringe (BD Discardit II, New Jersey). The contents 
of the syringe were injected into the chamber by an automatic pump (Harvard apparatus, 
Catalog no 98-4362). For each sample a 90 s video was captured with shutter set at 
1495 and gain at 400. The video was analyzed by using the NTA 2.0 Build 127 software. The 
following settings were used for tracking of the particles: background extract on; brightness 
0; gain 1.00; blur size 3x3; detection threshold 10, viscosity equal to that of water. All other 
parameters were set to the automatic adjustment mode.
Flow imaging microscopy
A Micro-Flow Imaging (MFI) system (MFI5200, ProteinSimple, Santa Clara, USA), equipped 
with a silane coated flow cell (1.41 x 1.76 x 0.1 mm) and controlled by the MFI View System 
Software (MVSS) version 2, was used for flow imaging microscopy analysis. The system 
was flushed with 4 mL purified water at 6 mL/min prior to each measurement. The flow cell 
cleanliness was checked visually between measurements. The background was zeroed 
by flowing 10 mM phosphate buffer, pH 6.2, and performing the ‘optimize illumination’ 
procedure. Samples of 0.5 mL with a pre-run volume of 0.2 mL were analyzed at a flow rate 
of 0.17 mL/min and a fixed camera rate of 22 flashes per second. 
The data recorded by the MVSS was analyzed with MFI View Analysis Suite (MVAS) 
version 1.2. For each sample, stuck, edge and slow moving particles were removed by 
the software before data analysis. The equivalent circular diameter (ECD), which is the 
diameter of a circle that has an area equal to that of the particle imaged by MFI, was 
calculated and presented as a measure of the particle size.
Theoretical calculations
Fitting the experimental data with Smoluchowski’s perikinetic coagulation model 
The experimental data were plotted such that they illustrate the changes in total particle 
concentration over time, as particle collision leads to fusion into larger particles. These 
changes were fitted by a one-phase exponential decay equation: 
   Eq. 1
from which N0 (the initial total particle concentration) and τexp (the experimental half-life, 
i.e., the time at which the total concentration of particles reduces to half) were obtained. 
Knowing the initial total number of particles N0, Smoluchowski’s perikinetic coagulation 
theory was used to predict a theoretical half-life (τtheor) by assuming that all particle collisions 
lead to fusion: 
         Eq. 2
where µ is the viscosity of the buffer, KB the Boltzmann constant and T the absolute 
temperature.  The sticking probability (α), defined as the fraction of particles remaining in 
contact after collision24, was calculated from the ratio between τtheor and τexp:
       Eq. 3
Equation 1 was used to fit the experimental data for measurements with different starting 
concentrations (using GraphPad Prism version 5). Subsequently, the collision efficiency for 
each condition was calculated and compared. 
Results
In order to monitor the particle formation and growth we performed simultaneous NTA and 
MFI measurements at different time points after mixing equal volumes of IgG and dextran 
sulfate solutions, yielding a final concentration of 0.05 mg/ml IgG and 0.05 mg/ml dextran 
sulfate. The amount of free IgG was measured by SEC after spinning down the formed 
particles. 
The amount of free IgG monomer in the control (IgG alone) and prepared dextran 
sulfate/IgG mixture  taken at three specified time points (see Figure 1) as measured by 
SEC is shown in Figure 2. The appearance of the pellet after spinning down the mixture 
was a solid precipitate.  
Figure 2: SEC results of centrifuged 
IgG/dextran sulfate (1:1 w/w, total 
concentration 0.01 mg/ml) mixtures, 
shown as percentage of IgG left in 
the solution at different incubation 
time points. The reference bar is 
0.01 mg/ml IgG solution diluted 
twofold with 10 mM phosphate 
buffer, pH 6.2. The measurement at 4 hours after preparation did not show any IgG peak at 
all (*).
Figure 3: Results of NTA of IgG/dextran sulfate (1:1 w/w, total concentration 0.01 mg/ml) 
mixtures as function of incubation time. Graphs show the total particle concentrations 
(logarithmic scale) for each 100-nm wide size category within the size range between 
100-800 nm at different time points (A: 101-400 nm; B: 401-800 nm). The size categories were 
split into two graphs for sake of clarity. The results of duplicate experiments are incorporated 
in the graphs, where each dot represents the mean and the bars the highest and lowest value. 
The connecting lines serve as a guidance to clarify the progress of the particle concentration 
of the different populations.
Compared to the reference sample, all samples showed a great decrease in free IgG 
monomer content, down to 12%, 5% and 0%, at 2, 120 and 240 min, respectively, after 
starting the incubation. Even though this SEC column showed to be suitable to separate 
up to IgG tetramers, no oligomer peaks were detected by SEC for any of the samples, 
suggesting that the IgG monomers are rapidly included in particles that are too large to 
pass the SEC column and/or particles that are spun down during the centrifugation step 
prior to SEC analysis.
Nanoparticle tracking analysis (NTA)
Figure 4: Total particle concentration 
within the 100-800 nm size range (black 
squares) and average particle size (green 
circles) of IgG/dextran sulfate (1:1 w/w, 
total concentration 0.01 mg/ml) mixtures, 
measured with NTA as function of 
experiments are incorporated in the graph, where each data point represents the mean and 
the bars the higher and the lower value.
The generated size distribution curves obtained from NTA were sliced in segments of 
100 nm bins and the total concentrations of particles within these segments at different 
time points were plotted. The lower detection limit of NanoSight is about 40 nm (depending 
on the light scattering properties of the particles), therefore the segmentation was started 
from 100 nm. Size bins over 800 nm were not included because no reliable data could be 
obtained (further explained in the Discussion section). The total concentrations of particles 
in the categories between 100 and 500 nm were relatively high and decreased with time 
already from the beginning (Figure 3A), whereas the larger size ranges showed an increase 
in particle concentration after the start of the experiment, which gradually stabilized and 
started to decrease at later time points (Figure 3B). The total nanoparticle concentration 
(population with a size between 100-800 nm) and the associated average particle size of 
this population over time are shown in Figure 4. The total particle concentration decreased 
exponentially with an increase in mean size in the first hour of the study timespan.
Figure 5: Results of MFI of IgG/dextran 
sulfate (1:1 w/w, total concentration 
0.01 mg/ml) mixtures as function of 
incubation time. Graph shows the total 
particle concentrations (logarithmic scale) 
for each 1-μm wide size category within the 
size range between 1-6 μm at different time 
points. The results of duplicate experiments are incorporated in the graph, where each dot 
represents the mean and the bars the highest and lowest value. 
Flow imaging microscopy was used to monitor the concentration and size distribution of 
particles in the micrometer-size range. Figure 5 shows the particle concentration as function 
of time, plotted by grouping the particles in 1-μm wide size bins, displayed up to 6 µm (the 
contribution of larger particles to the total particle count was negligible). 
The particle concentration in the size range covered by the MFI instrument started to increase 
rapidly from about 1.5 hour after the start of the experiment. These particles were mainly in 
the size range between 1-2 μm. Interestingly, when the rate of increase in the concentration 
of 1-2 μm particles started to decrease, particles in the range of 2-3 μm began to form at 
a fast rate; when the increase in concentration of the latter size range started to level off, 
3-4 μm sized particles started to form. Similar trends continued to happen successively for 
the larger particle sizes too. The total concentration of μm-range particles increased over 
time and reached its maximum at about 10 h, after which it started to drop gradually, while 
the average size of the particles increased gradually over time after an apparent decrease 
within the first minutes of the experiment (Figure 6). 
Figure 6: Total particle concentration 
within the 1-6 μm size range (black 
squares) and average particle size 
(green circles) of IgG/dextran sulfate 
(1:1 w/w, total concentration 
0.01 mg/ml) mixtures, measured with 
MFI as function of incubation time. 
The results of duplicate experiments are incorporated in the graph, where each data point 
represents the mean and the bars the higher and the lower value.
NTA and flow imaging microscopy results combined 
In order to visualize the overall development of particle formation and growth, as studied 
by NTA and MFI, the raw data generated by each method was used to plot the distribution 
of particles of different sizes over time in a single graph (Figure 7). 
This graph shows that a large number of nm-range particles were detected soon after the 
mixing of the protein and the polyelectrolyte, while no µm-range particles were detected 
at early time points. The particle size progressively increased with incubation time and the 
trend was clear toward the formation of µm-range particles within hours and a simultaneous 
decrease in the number of nm-range particles. 
Figure 7: Graphical representation of the 
particle growth in IgG/dextran sulfate (1:1 
w/w, total concentration 
0.01 mg/ml) mixtures, as monitored by 
NTA and MFI (based on the data sets 
shown in Figures 3-6). Scatter plot shows 
the size of individual particles (dots) 
detected by NTA and MFI in a volume of 
50 μL at each time point (non-linear time 
axis). Particles detected by NTA measurements are shown in the lower part (100-800 nm), 
the ones from MFI in the upper part (1000-6000 nm). The grey bar represents the area that 
is not covered by both techniques. For each time point, the calculated average size and the 
corresponding standard deviation are indicated in red. 
Fitting the experimental data into Smoluchowski’s perikinetic coagulation model 
The decrease in total particle concentration measured with NTA and MFI were fitted in a 
one-phase exponential decay formula (Eq. 1). For the concentration of 0.01 mg/ml the 
fitted exponential decay resulted in a N0 value of 1.29 x 109 particles per mL and a τexp of 
12.8 minutes (95% confidence intervals (CI): 8.1 – 31.1 minutes). With the help of Eq. 2 
deduced N0 value, the τtheor was calculated to be 2.5 minutes. The sticking probability can 
be either calculated by taking the ratio of τtheor to τexp or directly from the deduced 
N0 and τexp values and the help of Eq. 3. For the condition with 0.01 mg/ml of total material 
concentration resulted in an average sticking probability of 0.19 (95% CI: 0.08 – 0.31). 
The same data fitting approach was applied for two other concentrations with equal 
IgG:dextran sulfate ratio. The rationale behind the chosen condition was the assumption 
that the nature of the particles, hence the kinetics of the coagulation, will stay the same. 
The best-fit curves for the different studied conditions are shown in Figure 8. The curves 
indicate that the lowest concentration of the mixture shows a much slower decay, hence a 
larger τexp (41.6 minutes (95% CI: 25.8 – 107.9 minutes) for a total concentration of 
0.005 mg/ml, versus 14.1 minutes (95% CI: 10.2 – 22.6 minutes) for 0.02 mg/ml), compared 
to the higher concentrations. Note that the NTA measurement of the 0.02 mg/ml sample at 
the first time point indicated a higher average size, compared to the other concentrations. 
This indicates that the particle coagulation for that concentration had proceeded to a further 
stage. Figure 8 also presents the average sticking probabilities (average values: 0.16 for 
0.005 mg/ml; 0.19 for 0.01 mg/ml; 0.18 for 0.02 mg/ml). The average values were not 
significantly different (one-way Anova test: P = 0.9573).
Figure 8: Total particle concentration over time for samples with 0.005, 0.01 and 0.02 mg/ml 
of each starting solution are shown. The solid lines show the best fit curve gained by using 
Equation 1 as a model. The graph in lower right corner presents the sticking probability 
calculated with the help of Equation 2 and 3. The error bars represent the 95% confidence 
interval.
Discussion
In this study we have shown the applicability of the combination of NTA and MFI for 
monitoring the particle formation and growth, when a dextran sulfate solution is added to 
an IgG solution. Analysis of particle concentration and size in both the nanometer- and the 
micrometer-size range as function of time provides a good insight into the kinetics of the 
particle formation process, in terms of both particle size and particle concentration. As soon 
as the protein and the polyelectrolyte are mixed, the solution becomes supersaturated and 
electrostatic interactions lead to rapid formation of protein-polyelectrolyte complexes11. At 
this point nucleation occurs with the appearance of primary particles, which is associated 
with a rapid loss of free monomeric IgG as demonstrated in our study by SEC analysis 
(Figure 2). This observation is in line with the literature reporting that the stage of aggregation 
of primary particles39 into flocks is the rate-limiting step in the formation and growth of larger 
particles40. 
In this study NTA proved to be a valuable tool to study the interaction kinetics in the early 
stage, where no micron-sized agglomerates are formed yet. However, the progressive 
increase in larger particle concentrations made the NTA measurements increasingly difficult 
to perform and eventually impossible. This is due to inaccuracies caused by the presence 
of large particles (over 800 nm) with multiple scattering centers that rapidly change position, 
which erroneously leads to the detection of apparent very small particles 
(smaller than 100 nm). 
Moreover, their brightness and size leads to masking and overlapping of particles. In 
addition, above this size the Brownian motion becomes very low, leading to additional 
inaccuracies28. This was the reason for applying NTA only for the first part of the coagulation 
process (up to 440 min) and excluding the particles with sizes larger than 800 nm and 
smaller than 100 nm. Continuously decreasing concentrations of particles in the lower 
nanometer size range (101-400 nm) were accompanied by an initial increase followed by 
a moderate decrease in concentrations of larger nanoparticles (> 400 nm), as shown in 
Figure 3. The exponential decrease in total nanoparticle concentration (Figure 4) indicates 
that over time the smaller particles coagulated in order to form larger particles. However, 
the average particle size measured by NTA only increased at the start and afterwards 
remained fairly constant. That can be explained by the chosen lower limit for the NTA data 
(101 nm), leading to underestimation of the number of smaller particles29. 
In the later stage of the coagulation process, when the particle size entered the micrometer 
range, MFI took over the role of NTA to monitor particle growth. By displaying the measured 
microparticle size classes in 1-μm bins, the consistency and precision of the technique in 
monitoring the particle growth process was revealed (Figure 5). The course of the total 
particle concentration showed a rapid growth, starting at about 90 minutes, and began 
to decrease slightly after about 600 minutes (Figure 6). This indicates that around this 
moment the low-nanometer particle population became depleted, while the growth within 
the micrometer range continued. The average particle size provided by the MFI was very 
large at the start, with a broad range, while the particle counts were very low. These results 
are comparable to those obtained when only IgG or dextran sulfate solution was measured, 
pointing to the presence of small amounts of particulate impurities or contaminants in 
the starting materials. The average particle size by the end of the experiment was well 
below 5 µm, which is too small to provide us with reliable morphological parameters27. 
The perikinetic coagulation theory, developed by Smoluchowski about a century ago, 
predicts the kinetics of particle growth due to Brownian motion driven collision of particles, 
with subsequent fusion into larger particles35,36. This theory has been frequently used to 
derive information about the time evolution of the particle concentration as they cluster 
together. For instance, Fisher et al. used a Smoluchowski based population-balance model 
to describe the precipitation behavior of lysozyme by polyacrylic acid41. Chen et al. used 
Smoluchowski’s perikinetic coagulation theory to describe the effect of mixing conditions 
on the flocculation kinetics of proteins in wastewater42. In our study the experimental data 
was fitted with a simple exponential decay model (Eq. 1), in order to deduce the initial 
particle concentration (N0) and the experimental half-life (τexp). This was performed for 3 
different concentrations of the starting materials (with equal mass ratios of the components 
in each). The physicochemical nature of the formed complexes restricts the success of 
each collision to fuse into a new larger particle. In case of protein-polyelectrolyte particles 
the surface could possess a net charge43, which causes repulsion of similarly charged 
particles. However, polyelectrolyte bridging in-between particles is the main mechanism 
behind coagulation of protein-polyelectrolyte complexes44. With respect to this restriction, 
the Smoluchowski model has some limitations, such as the assumptions that the colliding 
particles are spherical; every collision involves two particles of identical initial size; and each 
collision leads to a successful fusion24, meaning that the sticking probability is unity and 
independent of the particle size. This is very unlikely and probably explains the difference 
between the experimental and theoretical half-life. With the deduced parameters from the 
fitting, we have calculated the collision efficiencies, which matched very well between the 
samples with different IgG and dextran sulfate concentrations. 
Conclusion
The combination of NTA and MFI allowed us to analyze the growth kinetics of IgG/dextran 
sulfate complexes. Our data suggest that electrostatic interactions between IgG and dextran 
sulfate rapidly lead to the formation of particles. Due to particle collision these primary 
particles fuse and start to increase in size, leading to a rapid decrease in total nanoparticle 
concentration and a concomitant increase of new particles that grow further till they reach 
a size of 1-2 µm. The particle formation process could be described with the coagulation 
theory of Smoluchowski, provided that a collision efficiency term was introduced. Our 
approach provides novel insight into the kinetics and mechanism of protein-polyelectrolyte 
complex formation and can be applied to other systems, such as complexes between 
polyelectrolytes and proteins, DNA, or other biomacromolecules.
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Abstract
Purpose. To investigate whether particle sedimentation velocity tracking using a flow 
imaging microscope (FlowCAM) can be used to determine microparticle porosity. 
Methods. Two different methods were explored. In the first method the sedimentation rate 
of microparticles was tracked in suspending media with different densities. The porosity 
was calculated from the average apparent density of the particles derived by intra- or 
extrapolation to the density of a suspending medium in which the sedimentation velocity 
was zero. In the second method, the microparticle size and sedimentation velocity in one 
suspending fluid were used to calculate the density and porosity of individual particles by 
using the Stokes’ law of sedimentation. 
Results. Polystyrene beads of different sizes were used for the development, optimization 
and validation of the methods. For both methods we found porosity values that were in 
excellent agreement with the expected values. Both methods were applied to determine 
the porosity of three PLGA microparticle batches with different porosities (between about 
4 and 52%). With both methods we obtained microparticle porosity values similar to those 
obtained by mercury intrusion porosimetry. 
Conclusion. We developed two methods to determine average microparticle density and 
porosity by sedimentation velocity tracking, using only a few milligrams of powder.
Introduction
Formulating active pharmaceutical ingredients (API) in controlled release systems is a potent 
strategy to maintain drug levels for prolonged periods within the therapeutic window, which 
may increase the efficiency of therapy, reduce the costs and improve patient compliance 
and comfort (1). Owing to their long clinical experience and favorable performance in terms 
of biodegradability and biocompatibility, PLGA microparticles fulfill the needs for controlled 
release in the area of parenteral pharmaceutical formulations, with a number of FDA 
approved drug products on the market today (2). 
The porosity or void fraction of poly lactic-co-glycolic acid (PLGA) microparticles is a 
critical parameter known to affect the release kinetics of encapsulated drugs (3-5). Current 
approaches to determine the porosity of particulate drug delivery systems are based on 
established methods used in agricultural, petrochemical and constructional engineering 
(6). Among the available methods, mercury intrusion porosimetry (MIP) and gas (nitrogen) 
adsorption based methods are the most common and informative ones, because both can 
measure the pore size and its distribution. In addition, mercury porosimetry has the advantage 
of having certified reference material and standard measurement protocols (7). However, 
each of these methods has a number of major drawbacks. For instance, both methods 
require large amounts of sample (200-300 mg) for a single measurement. In addition, with 
MIP the difficulties are seen in distinguishing intra- and interparticulate pores (8). Besides, 
presence of enclosed pores may need additional MIP measurements with grinded material 
(9) and ink-bottle shaped and interconnected pores can lead to underestimation of the pore 
size (8). Toxic metal waste is yet another reason that would make the application of MIP 
less favorable. In contrast to MIP, with gas adsorption methods both open and enclosed 
pores are measured; however, the process of pressure equilibration may be very slow, 
resulting in long-lasting measurements for a single sample. Last but not least, although 
fully automated equipment is commercially available for both methods, such equipment is 
expensive and not available in many pharmaceutical laboratories. 
Taking into account the drawbacks of the methods described above, there is need for a 
more straightforward method requiring small amounts of sample for deriving the overall 
porosity of (pharmaceutical) particulate systems. Considering the developments in flow 
imaging instruments with respect to image quality, sizing precision and accuracy (10) 
and their increasingly widespread use in pharmaceutical laboratories, we have evaluated 
sedimentation velocity tracking using a flow imaging microscope (FlowCAM) for measuring 
the density and porosity of PLGA microparticles. To our knowledge, in spite of the simplicity 
of the concept, a sedimentation based approach has not been used before to measure 
particle porosity. The velocity of a settling particle depends among other parameters on 
the size of the particle and the density difference between the liquid and the particle (11). 
The density of each component of a microparticle (e.g., PLGA matrix, drug, and liquid or 
air filling the pores) contributes proportionally to the total microparticle density, and can 
therefore be used to calculate the porosity of a microparticle. 
Here we present two methods using a FlowCAM to determine the porosity of PLGA 
microparticles. The results show that both methods generate porosity values close to those 
obtained with MIP, but require much smaller amounts of sample. 
Materials and Methods
Materials
Cesium chloride (CsCl), polysorbate 80 and ethanol were obtained from Sigma (Sigma-
Aldrich, Steinheim, Germany). Phosphate buffered saline (PBS; 8.2 g/L NaCl, 3.1 g/L 
Na2HPO4.12H2O, 0.3 g/L NaH2PO4.2H2O, pH 7.4) was purchased from Braun (B. Braun 
Melsungen AG, Germany) and filtered with a 0.22-µm polyethersulfone-based syringe-
driven filter unit (Millex GP, Millipore, Carrigtwohill, Ireland). Ultrapure water (18.2 MΩ.cm) 
was dispensed by using a Purelab Ultra water purification system (ELGA LabWater, 
Marlow, UK). Non-porous polystyrene sizing standards of different sizes (29.8 ± 0.4, 50.2 
± 0.5 and 69.1 ± 0.8 μm) were purchased from Duke Scientific (through Thermo Scientific, 
Fremont, CA, USA). Three batches of dried PLGA microparticles were kindly provided by 
Dr. Reddy’s (IPDO, Leiden, the Netherlands). One of these batches (batch 1) contained 
no active pharmaceutical ingredient (API). The other two batches (2 and 3) were loaded 
with different amounts of an API. The microparticle batches had different porosities as 
measured with MIP, namely 4.0, 21.6, and 51.9% for batch 1, 2 and 3, respectively. The 
residual water content and residual organic solvent content of each PLGA microparticle 
batch were found to be lower than 0.5% (w/w) and were not taken into account.
Surface morphometry using scanning electron microscopy
Scanning electron microscopy (SEM, Nova NanoSEM, FEI, Eindhoven, the Netherlands) 
was used for high resolution imaging of the surface of PLGA microparticles. Microparticles 
were coated with a thin layer of gold in order to increase the surface conductivity. The 
instrument was operated at 15 kV and images were taken at magnifications between 50 
and 400x. 
Sample preparation for sedimentation velocity tracking
Solutions of PBS containing 0.01% (w/v) polysorbate 80 (PBS-T) were prepared with 
varying fluid densities by adding different concentrations of CsCl. Polysorbate 80 was 
included to facilitate wetting of the microparticles. The concentration of CsCl ranged from 
0 – 75% (w/w), resulting in fluid densities ranging from about 1000 - 1655 kg/m3. The 
density and viscosity of the used suspending fluids were observed to be dependent on 
the concentration of CsCl, and were taken into account in further calculations. All the 
measurements were performed at room temperature. A few drops of the concentrated 
polystyrene sizing standards were added to 10 mL of the PBS-T / CsCl solutions. For each 
polystyrene standard suspension, the sedimentation of 50 – 100 particles was tracked using 
FlowCAM. In order to study PLGA microparticle sedimentation, an appropriate amount of 
microparticles was suspended in PBS-T / CsCl to achieve a microparticle concentration of 
about 0.25 mg/mL (corresponding to approximately 7000 - 15000 particle counts/mL). These 
relatively low particle concentrations were chosen in order to avoid physical agglomeration 
and optical coincidence of settling particles. After addition of the suspending medium to the 
microparticles, the suspension was sonicated for 20 minutes and left at ambient conditions 
for at least 3 hours prior to analysis.
FlowCAM set-up for sedimentation velocity tracking
A FlowCAM VS1 system (Fluid Imaging Technologies, Yarmouth, ME, USA) equipped with a 
300-µm Field of View (FOV300; 300 µm depth and 1500 µm width) cell and 4x magnification 
lens was used in this study. VisualSpreadsheet software version 3 was used to control the 
system and to process the data. Prior to each measurement, the flow cell was rinsed with 
2 mL particle-free suspending medium corresponding to the sample being measured. The 
background was calibrated by manually priming 0.5 mL of the same particle-free suspending 
medium. Hereafter, 1.5 mL of the sample was loaded and FlowCAM measurement was 
started with a flow rate of 0.20 mL/min and a camera rate of 10 frames/s. As soon as the 
sample had completely filled the flow cell and tubing (based on the volume estimated from 
the flow cell and tubing dimensions), the tubing was disconnected from the pump and both 
tubing ends were clamped to create a closed system in which there is no liquid flow. The 
analysis was stopped manually as soon as a sufficient number of particles was tracked 
(50 – 100 particles). The sample volume was set to 10 mL in the software settings to avoid 
premature, automatic termination of the analysis.
Sedimentation velocity from FlowCAM data
In order to optimize the measurement and to minimize the risk of tracking impurities or 
particles with anomalous settling behavior, the following particle inclusion criteria were 
used:
1. Edge gradient (average intensity of the pixels making up the outside border of a   
particle) values between 100 – 200 a.u. and aspect ratio values above 0.9. This criterion 
selects only particles that are in focus. 
2. A distance of at least twice the diameter between the left/right edge of the particle and 
vertical sides of the flow cell (determined with the help of X-coordinate and the known 
width of the field of view). This criterion discards particles that undergo retardation in 
velocity due to the left and right edges of the flow cell.
3. A straight vertical movement path of the particle found when the X- and Y-coordinates 
at each image is plotted (i.e., X-coordinate does not change more than 5 pixels during the 
entire track). 
4. A constant particle displacement as a function of time. 
In this way, only accurately sized particles without any unordinary settling motion were 
used for sedimentation velocity tracking. 
The particles with properties that met the aforementioned criteria were extracted from the 
entire set of raw data. The Y-coordinate values (expressed in pixels) were converted to metric 
distances, with the use of image scale (named calibration factor in VisualSpreadsheet). 
After plotting the time (in seconds) against metric displacement, the velocity was found as 
slope of the linear regression with the help of Excel 2010 software. 
In addition, the average values for properties such as area based diameter (ABD, the 
diameter based on a circle with an area that is equal to the projected particle area) and 
aspect ratio were extracted for each tracked particle.
Method I: PLGA microparticle porosity from sedimentation velocity in fluids with 
varying densities (density-matching method)
The first approach that was used to derive the density and, subsequently, the porosity of 
analyzed particles consisted of tracking the individual particle sedimentation velocity in 
fluids with different densities. For each bead or microparticle suspension, the sedimentation 
velocity of individual particles was derived as described above. In order to normalize the 
derived velocities (v, in m/s) for particle size, they were divided by the corresponding 
average square diameter (calculated from ABD values; d2, in m2). The resulting particle 
size-normalized sedimentation velocity (v/d2, in m-1s-1) values were based on the relation 
between velocity and diameter found in Stokes` law of sedimentation, as shown in Eq. 1:
Eq. 1
where ρp and ρf are the particle and fluid densities (in kg/m3), respectively, µ is the dynamic 
viscosity of the fluid (in kg/m.s) and g is the gravitational acceleration (m/s2). Note that 
(particle size-normalized) sedimentation velocity values will be positive for settling particles 
and negative for floating particles. 
Subsequently, the average v/d2 values for each bead size or PLGA microparticle batch 
in different suspending media were plotted against the density of the corresponding 
suspending medium. Assuming that the particle would stagnate when its density is equal to 
that of the liquid, the intercept of a linear regression with the X-axis (density axis) was taken 
as the average particle density of the concerning polystyrene bead or PLGA microparticle 
batch. In case of a porous particle containing an active pharmaceutical ingredient (API), the 
particle density will be the sum of the fractional densities of (i) the matrix (fPLGA × ρPLGA), (ii) 
the API (fAPI × ρAPI) and (iii) the pores (fpore × ρpore). Assuming that the pores are filled with air 
(i.e., ρpore = 0; further explained in the Discussion section), Eq. 2 was used to calculate the 
density derived particle porosity (φ in %) (6): 
Eq. 2
where  in which ρsolid is the density of the solids, i.e., API and the PLGA matrix, and fAPI and 
fPLGA are the weight fractions of the API and the PLGA, respectively, in the solids content 
(derived from the drug loading in percent). 
Method II: PLGA microparticle porosity from sedimentation velocity using Stokes’ 
law (Stokes derived method) 
For the second method only the particles tracked in a suspending fluid having a density 
close, but not equal, to the expected particle density were used. As compared to high 
sedimentation velocities, low sedimentation velocities result in more accurate density 
determinations, because of the large number of 2D-coordinate data points gained from a 
large number of images taken during the particle tracking time lapse. Subsequently, the 
density and resulting porosity of individual particles were calculated, by means of Stokes’ 
law. 
Bach et al. derived equations for calculating the density of a settling particle in a fluid (12). 
Here, we used the same approach, but with porosity of the particle as the final outcome. The 
Stokes’ law of sedimentation was used as a starting point for the calculations. This formula 
gives a mathematical description for the drag force exerted on spherical objects when the 
Reynolds number is very small (Re << 0.1) (13). The Reynolds numbers associated with 
the relative flow of particles tracked in our study were calculated to be << 0.01, using Eq. 3:
          
Eq. 3
Incorporating equivalent of ρp from equation 2 in equation 1, and rewriting it to porosity (%) 
leaves us with the following:
       Eq. 4
In our calculations, in case of particle diameters equal to or larger than 50 µm we also 
applied a correction for the sedimentation velocity with respect to the retarding effect by the 
presence of the FlowCAM cell wall:
          Eq. 5
Here, the experimentally measured velocity (vmeasured) is corrected for coefficient of drag 
(k), particle diameter (d) and the shortest distance of the particle edge and the wall (D), 
to eventually gain the velocity corrected for the wall effect (vwc). The coefficient of drag 
depends on the shape of the space where settling takes place, and had a value of 1.004 
(12). We also took into account the effect of particle shape on the sedimentation velocity. 
For this purpose, based on the FlowCAM and SEM images, we have used the corrections 
specifically for prolate ellipsoid shapes (14):
        
Eq. 6
                                                                  where 
where β is the reciprocal aspect ratio. As seen in equation 6, the final velocity (v) is achieved 
by correcting the wall-effect-corrected velocity (vwc) using the average aspect ratio of each 
particle from the analyzed FlowCAM data.
Results
Sedimentation velocity data processing and analysis set-up using polystyrene beads
FlowCAM was used to determine the sedimentation velocity of microparticles in aqueous 
liquids. The velocity value was then used to derive the density of the microparticles. From 
the density and known composition of the microparticles the porosity was calculated. 
Derivation of the sedimentation criteria to include a particle in the density calculations, 
corrections for influential parameters on the sedimentation (e.g., wall and shape effect) and 
the validation of the method were studied and performed by using polystyrene beads of 
three different sizes. In the supplementary document the development of the first selection 
criterion (Supplementary Figure S1) and the wall correction (Supplementary Figure S2) are 
explained in detail. 
Figure 1: Theoretical sedimentation velocities 
plotted against experimental sedimentation 
velocities of polystyrene size standards 
suspended in liquids with different densities: 
30-µm beads (black circles), 50-µm beads 
(blue circles) and 70-µm beads (orange 
circles). For the 50-µm and 70-µm beads, 
a correction for the wall effect was applied. 
The theoretical sedimentation velocity was 
calculated by using the measured size of 
the concerning particle and the bead density 
(1050 kg/m3) as provided by the manufacturer.
Figure 1 shows that the experimental sedimentation velocities (corrected for the wall effect) 
of all the polystyrene beads are in excellent correspondence with the theoretical values. This 
indicates that determining the density through measurement of the sedimentation velocity 
using a FlowCAM is possible for particles widely ranging in size and density difference (with 
respect to the suspending liquid), when applying the inclusion criteria named in Materials 
Figure 2: Polystyrene bead displacements in the 2-dimensional plain (graph A) and in time 
(graph B). The position of a settling particle in each image captured by FlowCAM is given by 
the X- and Y-coordinates in terms of pixel number from the lower left corner. This way the 
path of a settling particle can be derived, by making a scatter plot of the coordinates against 
the tracked time. This is illustrated in graph A for a number of beads of each polystyrene size 
standard (30-µm beads in black; 50-µm beads in blue; 70-µm beads in orange). In graph B the 
displacement in the Y-axis over time of the particles from graph A are shown. The slopes of 
these lines represent individual settling velocities (pix/s).
The complete data set of the particles fulfilling the inclusion criteria was extracted from 
the raw data and the physical displacement through the field of view was visualized by 
plotting the X- and Y-coordinates, as shown in Figure 2A. At this point only the particles 
with a settling distance from the left or right flow cell border of at least two times the particle 
diameter and showing a vertical settling path were selected to be included in the analysis. 
In the last step of data processing, the vertical displacement was plotted against time, for 
individual particles, where the slope of the deduced line corresponds to the sedimentation 
velocity of the particle. Figure 2B illustrates that the slopes, representing the sedimentation 
velocities, increase with increasing polystyrene bead size, as expected.
The same polystyrene beads of different sizes were used to validate the two methods 
applied in our study. For Method I (the density-matching method), particle sedimentation 
velocities were determined in liquids with different densities and the results are shown in 
Figure 3. The relation between fluid density and particle size-normalized sedimentation 
velocity (v/d2) was shown to be linear (R2 above 0.97), with nearly the same slope for all 
beads (-2206 ± 45 vs. -2127 ± 87; -2253 ± 36 for 30-, 50- and 70-µm beads, respectively). 
Method validation using polystyrene beads
Figure 3: The validation results of the two sedimentation based methods for porosity 
measurements, using polystyrene size standards. Panels A – C show the relation between 
fluid density and particle size-normalized sedimentation velocity (v/d2) for 30-µm, 50-µm and 
70-µm beads, respectively. Each data point represents the average and standard deviation 
of the v/d2 derived from tracking of at least 20 individual particles in the corresponding fluid 
density. The linear relation between fluid density and sedimentation velocity is denoted as 
the solid line, with the 95% confidence of interval of the linear relation between the dashed 
lines. Note that only for 50-µm and 70-µm beads the attained velocities were corrected for 
the wall effect. Panel D shows density distributions of the investigated polystyrene beads in 
fluids closest to the nominal polystyrene density (i.e., fluid density of 1040, 1052 and 
1060 kg/m3, respectively, for 30-, 50- and 70-μm beads).
Using linear regression on the data points helped finding the intercept with the X-axis, which 
corresponds to the average density of the corresponding particles. In case of polystyrene 
beads the derived particle density appeared to be statistically equal to the reference values 
from the manufacturer (see Table 1). Altogether, these results demonstrate the validity of 
the method. 
For Method II (the Stokes derived method) only the data from a fluid having a density close 
to the expected bead density was used in order to obtain sedimentation velocity values 
with the highest possible accuracy. As explained in the Materials and Methods section, the 
individual particle velocities were used to calculate the particle density through Stokes’ law 
of sedimentation, after corrections for shape and wall effect. The results listed in Table 1 
show that the polystyrene bead densities determined for each bead size were comparable 
to the specifications from the manufacturer. With Method II the density distribution of the 
polystyrene beads could be derived, as shown in Figure 3D. Moreover, from the ratio of 
the calculated and given density distribution the porosity distributions were derived. The 
porosity values of polystyrene beads were calculated to be in the range of 0.1 ± 0.1% for 
30 and 50 μm beads and 0.0 ± 0.1% for the 70 μm beads, which is in excellent agreement 
with the expected value of zero for solid beads. 
In conclusion, we have established two valid methods to determine microparticle density 
and porosity based on sedimentation velocity tracking. In addition, with Method II, one is 
able to derive the density distribution and hence the porosity distribution.
Sedimentation velocity tracking for determining PLGA microparticle porosity
The shape of the PLGA microparticles was studied by using the images and morphological 
data provided by FlowCAM as well as with SEM imaging (Figure 4). Batches 1 and 2 
appeared to have predominantly spherical particles with a smooth surface, whereas batch 
3 contained mainly misshaped particles, with highly irregular surfaces. Also with FlowCAM, 
these morphological properties were distinguishable, albeit with a less detailed resolution 
compared to SEM. These differences were apparent from a number of morphological 
descriptors, in particular aspect ratio, circle fit, circularity, intensity and transparency 
(Table 2).
Table 1: Densities of polystyrene beads obtained by sedimentation velocity tracking with 
the density-matching method (Method I) and the Stokes derived method 
(Method II).
1 mean and standard deviation ((SD), derived from measurements in 5-6 different 
suspending liquids) of the density and the goodness of fit. 
2 density distributions (n = 20 particles) 
Table 2: Morphological parameters of the different PLGA microparticle batches. 
*Significantly different from the other batch(es) (one-way Anova (p<0.0001) followed by 
post-hoc Tukey’s multiple comparison test (p<0.05))
compared to SEM. These differences were apparent from a number of morphological 
descriptors, in particular aspect ratio, circle fit, circularity, intensity and transparency 
(Table 2).
Figure 4: Representative high resolution scanning electron microscopy (upper panels) and 
FlowCAM images (lower panels) of the different PLGA microparticle batches.
The two validated methods were then used to obtain the microparticle porosity, derived 
from the density (calculated as shown in the Materials and Methods section), for 3 different 
PLGA microparticle batches. As shown in Figure 5A-C, for each of the batches a linear 
relation was found between fluid density and average v/d2, with a R2 value above 0.9. 
According to the density-matching method (Method I), the regression model for each batch 
was used to find the X-intercept, representing the average microparticle density, which 
resulted for all batches in a similar porosity value as measured by MIP (Table 3). Noticeably, 
compared to the other two batches, batch 3 showed a relatively high standard deviation 
for the average porosity. In addition, the determined porosity of batch 3tended to be lower 
than that obtained by MIP. For all batches, the Stokes derived method (Method II) showed 
similar porosity values as compared to those obtained by Method I. For this purpose the 
results from the fluid density closest to the matching density value (data point closest to the 
X-intercept in Figure A-C) were used. Furthermore, for each batch the porosity distribution 
was derived. As shown in Figure 5D, a relatively broad porosity distribution was found for 
batch 3 as compared to the other batches.
Figure 5: Results of the two sedimentation based methods applied for porosity measurements 
of the different PLGA microparticle batches. Panels A – C show the relation between fluid 
density and particle size-normalized sedimentation velocity (v/d2) for three different batches 
(batch 1, 2 and 3, respectively). Each data point represents the average and standard deviation 
of the sedimentation velocities derived from tracking of at least 20 individual particles in the 
corresponding fluid density. The linear relation between fluid density and v/d2 is denoted as 
the solid line, with the 95% confidence of interval of the linear relation between the dashed 
lines. Panel D shows porosity distributions of the investigated PLGA microparticle batches in 
fluids closest to the nominal PLGA microparticle density (i.e., fluid density of 1233, 1023 and 
999 kg/m3, respectively, for batch 1, 2 and 3).
Discussion
With the increasing need for controlled drug release formulations, the characterization 
of these systems becomes increasingly important. This holds true in particular for the 
determination of the porosity, for which complex, time- and material-consuming methods 
such as MIP and gas adsorption are generally used. In our study we have evaluated the 
feasibility to determine the porosity of individual microparticles from their sedimentation 
rate in a liquid. Because of its reported applicability for sedimentation rate determination 
(12), we selected a FlowCAM for our investigation. Tracking of the sedimentation velocity 
of microparticles becomes possible by obstructing the liquid flow after introduction of the 
sample into the flow cell of the instrument. 
The precision and accuracy of sizing are very important for the purpose of obtaining 
the correct particle density by sedimentation velocity tracking. Fortunately, the methods 
developed here do not require the counting (and sizing) of all particles in the suspension, 
unlike in conventional applications of flow imaging microscopy where particle concentration 
often is an important output parameter (10). Therefore, we have explored possibilities to 
use the image-derived data of individual particles to select only particles that are in focus (to 
allow accurate sizing) and show regular settling behavior (to enable accurate determination 
of the sedimentation velocity). 
This resulted in a number of inclusion criteria that were used as indicators for the 
aforementioned characteristics (size and settling behavior). The considerable (quadratic) 
effect of particle diameter on the calculated sedimentation velocity (cf. Eq. 2) was in 
Table 3: Densities and porosities of 3 PLGA microparticle batches obtained by sedimentation 
velocity tracking with the density-matching method (Method I) and the Stokes derived 
method (Method II).
1 calculated from the known solid composition of the PLGA microparticle batch, assuming 
that the pores were filled with air (lower values) or suspending liquid (upper values). 2 mean 
and standard deviation ((SD), derived from measurements in 5-6 different suspending 
liquids) of the density and the goodness of fit. 3 density or porosity distributions 
(n = 20 particles).
particular important to consider. In order to decrease potential errors related to this effect, 
we investigated appropriate instrument settings for our method development. As FlowCAM 
offers the operator the advantage to choose the magnification, we have tested the influence 
of magnification magnitude on the sizing precision and accuracy of 5-µm and 20-µm beads 
in an additional study (Supplementary Figure S3). The outcome of that study indicates 
that the use of a lower lens magnification improves the sizing precision and accuracy of 
the instrument. An additional advantage of a lower magnification is that it would result in 
a larger field of view, thus in a larger sedimentation path that could be tracked, which is 
beneficial for the accuracy of the sedimentation velocity calculation. 
We found the edge gradient parameter to be a useful indicator for focus, and therewith for 
accuracy of the sizing. The intensity of the outer border of the particle determines the edge 
gradient value. Here, a low edge gradient number may indicate that the edge of the particle 
is spread out, as that happens with out-of-focus particles, and a very high value indicates 
a very sharp contrast at the edge of the particle. All the pixels inside the edge border are 
eventually used to determine the area of the particles, which in turn is used to calculate 
the diameter (ABD). Our study indicates that very sharp contrast leads to underestimation 
of the particle size and therefore both a lower and an upper limit for the edge gradient 
were included in the particle selection criteria (100 – 200 a.u.). The edge gradient values 
of the PLGA microparticles were found to lie between 75 and 223. Polystyrene beads 
showed overall comparable (very dark) greyscale intensity as the PLGA microparticles that 
we studied. Also the refractive index of PLGA and polystyrene do not differ that much 
(1.46 and 1.59, respectively). In this case it is valid to consider that the edge gradient 
range that is chosen based on the polystyrene bead study, would be suitable for the PLGA 
microparticles as well. In case one wants to study the density (and/or porosity) of more 
transparent microparticles, the edge gradient range that represents in-focus particles may 
differ. Furthermore, the focal plane in the flow cell is ideally positioned in the middle of the 
depth of field of view, where particles in focus are assumed to have the maximum distance 
from the front and rear wall of the flow cell, hence the lowest resistance effects from these 
two walls. Despite these measures, one has to realize that the effect of imperfect focus and 
particle edge definition on the sizing may result in some errors in the density calculations 
and may be (at least partly) responsible for the distributions found for each group of the 
presumably uniformly dense polystyrene beads. 
The methods we developed here can be deterrent because they may seem to involve 
time-consuming processes. This holds true for the utilization of the inclusion criteria for a 
dataset of settling particles and for the procedure in Method I of tracking the sedimentation 
in different liquids and then finding the apparent density through intrapolation of the linear 
relation between fluid density and size-normalized sedimentation velocity (v/d2). However, 
the length of this part of the method can be easily reduced to even minutes if a computing 
toolbox based on a package like MatLab is used to test the named selection criteria on the 
whole data set and derivation of individual sedimentation rates with subsequent corrections 
and porosity calculations. This is particularly valuable when the method is used for routine 
analysis of, e.g., microparticle batches. 
Suspending fluids with a higher density than the expected particle density were chosen 
to confirm the applicability of the method for particles with a relatively low density, such 
as highly porous PLGA microparticles. Such particles would move upwards (float) in 
conventional suspending media, resulting in negative sedimentation velocity values. In 
the experiments where polystyrene beads of different sizes were found to be floating, the 
calculated densities were the same as provided by the manufacturer. This highlights the 
applicability of this method for a wide range of particle sizes, densities and porosities. The 
altered conditions in our study concerned fluid density, but theoretically fluid viscosity could 
be another parameter to adjust. 
For the density calculations using Stokes’ formula we have only used the data of particles 
in fluids with a density close to the particle density. In addition, as seen from Figure 1, the 
precision of the sedimentation velocity determination increases when the particle density is 
close to the fluid density. A significant added value of Method II over Method I lies in the fact 
that the final mean and standard deviation of the density (and hence porosity) from second 
approach resembles the population mean and the variability in it. In Method I the averages 
and standard deviations of different populations in different liquids are used to calculate a 
mean and standard deviation of the batch density (and porosity). 
One has to realize that the first raw outcome of the approaches presented in this study is 
the sedimentation velocity of particles, which is proportional to the apparent density of the 
particle. Therefore, the method is a reliable approach for measurement of the density of 
the particles as evidenced by investigation of the standard polystyrene beads. Deduction of 
porosity from the apparent density needs some assumptions, the most important of which 
concerns the filling of the pores, with air or suspending fluid. 
In a preliminary study we have investigated the effect of the time lag (up to 4 days) between 
the preparation of the microparticle suspension (batch 3) and the measurement. We found 
that the equilibration time did influence the density of the particles, especially after 24 h 
of incubation. This may be caused by a change of pore properties due to release of the 
API and potential degradation of the PLGA. Therefore, we fixed the equilibration time to 
3 hours, which should be long enough for wetting of the surface of the particles and short 
enough to avoid major changes in the pore properties. 
Considering the hydrophobic properties of the PLGA and the use of aqueous suspending 
media, one can expect that the diffusion of water through a primarily hydrophobic matrix 
would be considerably delayed. The assumption of air-filled pores for the porosity calculations 
appeared to be fair when the MIP data was compared to the porosity calculations based 
on flow imaging experiments. The results summarized in Table 4 indicate that the obtained 
densities of the PLGA particles from all batches are closer to those calculated from the MIP 
porosity data when pores are assumed to be filled with air. It has to be realized, however, 
that partial filling of the pores with liquid cannot be totally ruled out and it may be a source 
of the relatively large SD for batch 3 compared to the other 2 batches. 
Due to low nominal density of some PLGA particle batches and the presence of air-filled 
pores, getting a particle density higher than the density of water was not possible for all 
particles and therefore conditions for particle settling could not always be achieved, not 
even in absence of cesium chloride. Decreasing density of an aqueous solution can be 
realized by addition of alcohols. However, it was observed in a small experimental trial 
that the presence of ethanol caused aggregation of microparticles. Nevertheless, velocity 
measurements in different fluids showed a good linear relation, in terms of R2 values, in 
particular for the first two batches, suggesting that an extrapolation of the data points to 
obtain the intercept would be justified. PLGA microparticle batch 3 showed the lowest 
degree of linear fit and the lowest precision of the density and porosity determination. This 
may be due to the highly uneven shape and surface of these microparticles compared to 
the others, as well as the much higher porosity. Nevertheless, the obtained porosity was 
similar to the value obtained by MIP and significantly different (p < 0.05) from the porosities 
obtained for the other tested PLGA microparticles. 
With Method II sedimentation of individual particles is measured (therewith porosity of 
individual particles) and the mean and standard deviation of the investigated particle 
population is calculated. The larger relative standard deviation in the density (and hence 
porosity) that is seen for batch 3 may also be considered as an existing wide porosity 
distribution for this specific batch. Therefore, the second approach provides better insight 
into the porosity details on particle level, which is an advantage over Method I and the 
conventional methods for porosity determinations. 
Conclusion
In conclusion, we have developed, optimized and validated two sedimentation velocity 
tracking methods to assess the porosity of micron sized particles. For this purpose we 
used a FlowCAM instrument, but it is expected that the methods can be transferred to 
other flow imaging microscopes as well. For three batches of PLGA microparticles widely 
differing in porosity, both methods yielded porosity values that were similar to the values 
obtained by MIP, while requiring up to 100-fold smaller amounts of material. The methods 
could therefore be useful as a viable alternative to conventional methods for determining 
microparticle density and porosity.  
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Supporting Information
Supplementary Figure S1: 
Area based diameter (ABD) of 
the three tested polystyrene 
beads plotted against the 
with the lowest (left pairs) medium (middle pairs) and highest (right pairs) edge gradient 
values. The paired images show on the left the original image of a particle and on the right 
an image with an edge trace. The edge gradient value provided by VisualSpreadsheet is 
the average intensity of the pixels making up the outside border of a particle. A low edge 
gradient number indicates that the edge of the particle is spread out, as that happens with 
out-of-focus particles, and a very high value indicates a very sharp contrast at the edge of 
the particle. The results from Figure 1 indicate that the edge gradient value between 100 
and 200 corresponds with an ABD value within the range of specifications. Therefore, the 
edge gradient value was included as one of the criteria for selection of particles for the 
calculations applied further. Furthermore, the focal plane in the flow cell is ideally positioned 
in the middle of the depth of field of view, where particles in focus are assumed to have the 
corresponding edge gradient value. The color 
of each open circle represents a single particle 
analyzed in a suspending medium having the 
density as indicated in the legend. The grey bar 
indicates the average and standard deviation of 
the size as stated by the manufacturer. Images 
on top of the graphs are deduced from the 
analysis, each pair corresponding to a particle 
Supplementary Figure S1: Area based diameter (ABD) of the three tested polystyrene 
beads plotted against the corresponding edge gradient value. The color of each open 
Supplementary Figure S2: Average and standard deviation of the measured v/d2 for 
different beads in liquids with different densities: 30-µm beads (black circles) 50 µm-beads 
(blue circles) and 70-µm beads (orange circles). Wall effect correction was (A) not applied, 
(B) applied for all beads, and (C) applied for 50- and 70-µm beads. In each graph the data 
points were fitted by linear regression. The slopes and R2 values of each linear regression 
are shown in the table. It is seen that the slopes of the linear regression depends on the 
bead size, despite the use of v/d2. When wall correction is applied for the two largest bead 
sizes, the slopes become similar. Therefore, based on this study we chose to apply wall 
correction only for the microparticles with the size equal to or higher than 50 µm.  
Supplementary Figure S3: Scatter plot showing the relation between edge gradient and 
area based diameter of 5-µm (left) and 20-µm (right) polystyrene beads (Thermo Scientific, 
Fremont, CA, USA), with different magnification lenses (i.e., 20x and 4x). The inserts of 
particle images show a number of representative particles in appointed parts of the scatter 
plot.
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Abstract
The release of drugs from poly(lactic-co-glycolic acid) (PLGA) microparticles depends to 
a large extent on the porosity of the particles. Therefore, porosity determination of PLGA 
microparticles is extremely important during pharmaceutical product development. Currently, 
mercury intrusion porosimetry (MIP) is widely used despite its disadvantages, such as the 
need for a large amount of sample (several hundreds of milligrams) and residual toxic 
waste. Here, we present a method based on estimation of the volume of a known mass 
(a few milligrams) of particles using Micro-Flow Imaging (MFI) to determine microparticle 
batch porosity. Factors that are critical for the accuracy of this method (i.e., particle 
concentration, density of the suspending fluid and post sample rinsing) were identified and 
measures were taken to minimize potential errors. The validity of the optimized method 
was confirmed by using non-porous polymethylmethacrylate microparticles. Finally, the 
method was employed for the analysis of seven different PLGA microparticle batches with 
various porosities (4.0 – 51.9%) and drug loadings (0 – 38%). Obtained porosity values 
were in excellent agreement with the MIP derived porosities. Altogether, the developed MFI 
based method is an excellent tool for deriving the total volume of a known mass of particles 
and therewith the porosity of PLGA microparticles. 
Introduction
Particulate controlled release systems, such as poly(lactic-co-glycolic acid) (PLGA)-based 
microparticles, are established tools for increasing the therapeutic efficacy of small molecules 
and peptides by maintaining drug concentrations within target ranges1. This property also 
decreases side effects caused by peak concentrations and repeated administrations. The 
formulation design2 as well as the production method3 of drug-containing PLGA microparticles 
are determinative for the characteristics of the particles and hence their performance. 
Therefore, it is crucially important to have analytical methods available to measure the 
characteristics of PLGA microparticles. One of these characteristics is porosity, which is a 
measure of the volumetric void fraction of the particle. This parameter has been shown to 
greatly influence the burst release of the drug from PLGA microparticles4. Additionally, by 
enhancing the effective surface area pores can influence the extended release of the drug 
from the microparticles through several mechanisms5. 
Several analytical methods exist for determination of the porosity of microparticles, 
such as mercury intrusion porosimetry (MIP), gas expansion method, scanning electron 
microscopy (SEM)6. MIP is currently one of the most commonly employed methods for 
porosity determination because of its robustness and ability to provide in-depth porosity 
information. The popularity of MIP has led to the development of standardized protocols, 
reference materials and automatized equipment for this method7. However, the method 
has several disadvantages: it requires extensive expertise and model based calculation 
processes, the use of mercury generates toxic waste, and relatively large amounts 
(typically hundreds of milligrams) of powder are needed to perform the analysis which 
especially is a problem in the early stages of formulation and process development. Given 
the abovementioned disadvantages of MIP, there is a need for an economical, robust and 
straightforward analytical method for porosity determination. 
We hypothesized that flow imaging microscopy could be used for that purpose, because 
it accurately measures the number and size of microparticles8,9, requires relatively small 
amounts and does not generate toxic waste. This technique uses imaging of particles in 
suspension to derive the particle concentration, morphology and size distribution. In the 
previous chapter, we successfully determined PLGA microparticle porosity by tracking 
particle sedimentation velocity using a flow imaging microscope. In this study, we developed 
a new methodology, using flow imaging microscopy, to determine the porosity of PLGA 
microparticles by sizing and counting all microparticles in a suspension with a known mass 
of microparticles. This allows for determination of the total volume of the particles and, 
together with the known mass, one can calculate the density and therewith the porosity. The 
developed method was used for porosity determination of 7 different PLGA microparticle 
batches using only a few milligrams of powder.  
 Materials and Methods
Materials
Cesium chloride (CsCl) and polysorbate 80 were obtained from Sigma (Sigma-Aldrich, 
Steinheim, Germany). Phosphate buffered saline (PBS; 8.2 g/L NaCl, 3.1 g/L Na2HPO4.12H2O, 
0.3 g/L NaH2PO4.2H2O, pH 7.4) was purchased from Braun (B. Braun Melsungen AG, 
Germany) and filtered with a syringe driven 0.22-µm polyethersulfone filter unit (Millex 
GP, Millipore, Carrigtwohill, Ireland). Ultrapure water (18.2 MΩ.cm) was dispensed from a 
Purelab Ultra water purification system (ELGA LabWater, Marlow, UK). Solutions of PBS 
containing 0.01% (w/v) polysorbate 80 (PBS-T) were prepared to facilitate wetting of the 
particles. Dry polymethylmethacrylate polymer beads (PMMA; average size 14.7 ± 1.3 µm; 
non-porous with a density of 1.19 g/mL) were purchased from Polysciences Europe GmbH 
(Eppelheim, Germany). Seven batches of PLGA microparticles were kindly provided by 
Dr. Reddy’s (IPDO Leiden, the Netherlands). One of these batches contained no active 
pharmaceutical ingredient (API) and the other six were loaded with different amounts of 
API. A summary of these batches including their drug loading and porosity information 
(based on MIP) are shown in Table 1. The residual water and organic solvent contents of 
each PLGA microparticle batch were lower than 0.5% and not taken into account for the 
calculations. 
Table 1: Properties of the microparticle batches used in this study.
Batch MIP derived porosity 
(%)









Sample preparation for MFI measurements
For all the samples in individual studies about 1 mg of powder, accurately weighed using 
a microbalance (Sartorius model SE2, Goettingen, Germany) with a nominal resolution of 
0.1 µg, was used. Immediately after addition of the dry PMMA beads or PLGA microparticles 
to the suspending fluid (depending on desired concentration) the suspension was 
homogenized by vortexing. Thereafter, the suspension was sonicated for 20 minutes and 
left at ambient conditions for at least 24 hours. The suspension was vortexed again prior 
to the measurement. 
Testing influential parameters with PMMA beads
As part of method development multiple factors were tested, namely the density of the 
suspending fluid, the microparticle concentration and post-sample rinsing during the 
measurement (explained in detail in the next section). Different concentrations of CsCl 
were added to PBS-T in order to vary the fluid density. Fluid densities of 1.15 g/mL and 
1.27 g/mL were acquired with 0.63 g/mL and 1.25 g/mL CsCl, respectively. PMMA bead 
concentrations ranging from 0.1 mg/mL to 2.0 mg/mL were used for investigation of the 
effect of concentration on the accuracy of the method. 
MFI measurements 
Samples were analyzed by using a Micro Flow Imaging 5200 instrument (MFI; Protein 
Simple, Santa Clara, CA, USA) with MFI View System Software (MVSS) Version 2. The 
system was flushed with 3 mL of particle-free suspending fluid at 5 mL/min prior to each 
measurement. Flow cell cleanness was checked visually. The background was calibrated 
by performing the ‘optimize illumination’ procedure using particle-free suspension fluid. 
The MFI analysis was started without any discarded purge volume prior to the start of fluid 
imaging. For the study on the effect of concentration and density of the suspension, no 
post-sample rinsing was applied. The volume of the analyzed suspensions depended on 
the concentration of the sample, ranging from 0.5 mL to 10 mL. We strived to achieve at 
least 50,000 particle counts for the sake of statistical power of the measurement. 
A 5-mL pipette tip was placed at the sample introduction inlet of the MFI, into which the 
suspension was poured for analysis. The whole suspension of each sample was analyzed. 
The MFI measurements that included a post-sample rinsing procedure were accompanied 
by the following additional steps. Just before the end of the sample measurement, 0.5 mL 
of particle-free suspending fluid was used to rinse the sample container and was poured 
over the whole inner surface into the 5-mL pipette tip while continuing to measure with 
MFI. For the optimization of the MFI analysis (see results section), the potential effect of 
adsorbed particles at the container, pipette tip and inner tubing surfaces on the porosity 
calculations was investigated and the required extent of rinsing during the analysis was 
determined. The number of rinsing steps used to measure the PLGA microparticle batches 
was chosen based on the results from these optimization studies. No software filters were 
applied during the runs. After the runs, MFI View Analysis Suite (MVAS) version 1.4 was 
used to analyze the data recorded by MVSS and to remove stuck, edge and slow moving 
particles. In a preliminary study a simple filter was developed based on the Intensity 
parameter to exclude all contaminants (such as dust, fibers, etc.) from the analysis. For all 
samples only particles with a mean intensity value equal to or lower than 300 were included 
(total intensity range = 0 – 1023; with 0 corresponding to a black pixel and 1023 to a white 
pixel). The final size distribution of each sample was extracted, where the particle size was 
expressed as equivalent circular diameter (ECD), and used for further calculations.
Porosity calculations 
Porosity (φ) is basically the ratio of the pore volume (Vpores in mL) to the total volume of a 
given (known) amount of suspended particles (Vparticles in mL) in a certain sample volume. 
The total particle volume was calculated from the final measured size distribution (size 
over counts) by MFI. For this purpose each size bin (from 1 µm and larger, with steps of 
0.125 µm) was converted into a volume bin, by assuming a spherical shape. Thereafter, 
the sum of the multiplication of each bin volume with its corresponding total particle count 
was obtained. Vparticles consists of the total pore volume (Vpores in mL) and the skeletal volume 
(Vsolids in mL) or the volume of the solid components in the entire particle population within a 
given sample volume. Porosity is then calculated based on the following equation:
Eq. 1
Vsolids can be calculated from the mass of powder (m) that was used for the suspension and 
the density (ρsolids) of the solid components:
         Eq. 2
In case of PLGA microparticles the density can be calculated from the drug loading and the 
reported densities of the PLGA and API accordingly:
  Eq. 3
Here fAPI (hence drug loading) and fPLGA are the weight fractions of the API and the PLGA, 
respectively, in the solid content (derived from the drug loading). For the API and PLGA a 
density of 1.30 g/mL (as stated by the manufacturer of the microparticles) and 1.34 g/mL10, 
respectively, were used. By incorporating Eq. 3 into Eq. 2 and subsequently incorporating 
the resulting equation into Eq. 1, one can derive Eq. 4 to calculate the porosity of PLGA 
microspheres:
    Eq. 4
Results
Density of the suspending fluid
To optimize the sample preparation, we have investigated the influence of the density 
of the suspending fluid on the homogeneity of the PMMA bead suspension (in terms of 
particle concentration) during measurement. Homogeneity of the suspension is desired 
in order to minimize locally high particle concentrations that would lead to an increase of 
non-isolated particles. Non-isolated particles include true aggregates in the raw PMMA 
material, aggregates formed due to high bead concentration and optically overlapping 
particles during the measurement, all of which could compromise the accuracy of the 
method. The PMMA beads were suspended in PBS-T alone and in PBS-T containing 
two different concentrations of CsCl. For each suspension the total particle volume was 
measured with MFI. Thereafter, the analyzed particle volume relative to total particle 
volume at specific time points during the MFI measurement was calculated and the resulting 
graphs are presented in Figure 1. The error bars show the deviation caused by the size 
distribution of particles at different time points. Note that the size distribution becomes 
wider with the presence or increase in number of non-isolated particles. These graphics 
show in rough terms how changes in the density of the suspending fluid would influence 
the particle homogeneity in the sample liquid. All three graphs show low particle counts 
at 0 min due to initial dilution of the sample with the preceding particle-free suspending 
fluid used for the ‘optimize illumination’ step. At about 1 min, particle counts appeared to 
stabilize and all three graphs present a plateau stage. Suspending fluid containing no CsCl 
showed a slightly descending plateau stage, up to 3 minutes of measurement (Fig. 1A). 
Thereafter, the particle count decreased much faster. The standard deviation in the particle 
volume decreased at later stages of the plateau phase and thereafter. This indicates that 
percentage of non-isolated particles was not constant throughout the entire measurement. 
On the contrary, the suspending fluid with 0.63 g/mL CsCl having a density of 1.15 g/mL 
showed a much longer and more stable plateau stage (Fig. 1B). Here, the particle count 
started decreasing only after 4.5 min. During this measurement the standard deviation was 
relatively constant over a larger part of the plateau stage, indicating a constant percentage 
of non-isolated particles. Further increase of the fluid density to 1.27 g/mL (1.25 g/mL CsCl) 
resulted in relatively lower counts (Fig. 1C) during the first 3 minutes of the measurement 
compared to the other two suspensions. Thereafter, a progressive increase in analyzed 
particle volume was observed. A slight increase in the standard deviation of the particle 
volume was observed by the end of the measurement, indicating that the percentage of 
non-isolated particles increased towards the end of the measurement. 
Observations seen in this set of experiments indicate that a homogeneous particle 
concentration over the entire (or large part of) MFI measurement can be achieved using a
Figure 1: Percentage of the total particle volume over the measured time in samples of 
0.3 mg/mL PMMA beads in different suspending fluids: A) PBS and 0.01% polysorbate 80 
(density 1.03 g/mL); B) PBS, 0.01% polysorbate 80 and 0.63 g/mL CsCl (density 1.15 g/mL); 
and C) PBS, 0.01% polysorbate 80 and 1.25 g/mL CsCl (density 1.27 g/mL).
fluid density that matches the particle density. In our study we found a fluid density of 
1.15 g/mL to be the best choice with respect to homogeneity during the measurement 
of PMMA beads and therefore used this as suspending liquid in following studies. In this 
suspending liquid the density difference between the particles and the fluid was about 3% 
(relative to the PMMA density). 
Effect of particle concentration
During the second part of the study on influential factor, we focused on the particle 
concentration. Increasing particle concentration would theoretically result in increasing 
numbers of detected non-isolated, due to optically overlapping particles during the 
measurement. These non-isolated particles mostly do not have a spherical shape and 
therefore it is expected that the accuracy in total particle volume calculation would decrease 
with increasing number and volume of non-isolated particles. For this part, increasing 
concentrations of PMMA beads were prepared in duplicates using the suspending fluid with 
the density of 1.15 g/mL. After MFI measurement, the percentage of non-isolated particles 
(volume and number based) was calculated. 
Figure 2: The effect of PMMA bead concentration on the accuracy of total particle volume 
calculation. A: Contribution of non-isolated (sum of aggregated and optically overlapping) 
particles to the total particle counts (black circles) and total particle volume (red squares) 
in suspensions with different PMMA concentration, as measured with MFI. Each data 
point shows the average and the upper and lower value of the duplicate measurement of 
suspensions. Examples of MFI images of a single and a few different non-isolated particles 
are displayed below the graph. B: Total particle volume of each sample displayed in graph 
A as function of particle concentration. The theoretical values derived from the sample 
concentration and known PMMA density (black circles) and measured total particle volumes 
with MFI (red squares) are compared.
Figure 2A shows that an increasing bead concentration resulted in more non-isolated 
particles, as expected. This in turn led to an increase in the number and volume of the 
non-isolated particles relative to the total counts and total particle volume, respectively. At 
the highest bead concentration tested (2 mg/ml) almost 70% of the total particle volume 
belongs to non-isolated particles. Using the density of the PMMA particles and the PMMA 
sample concentrations, the total particle volume per sample (Vparticles) was calculated. In 
Figure 2B these theoretical values are compared with the experimentally determined total 
particle volume for each tested sample. It is seen that the measured particle volume started 
to significantly underestimate Vparticles at PMMA concentrations of 1 mg/mL and higher. For 
each following study with the PMMA beads a concentration of 0.1 mg/mL was used. 
Post-sample rinsing during MFI measurement
The last potentially influential factor that was studied concerned the measurement 
procedure. Here an attempt was made to minimize loss of sample, which would lead to 
erroneous total particle volume measurements. Loss of sample could be due to adsorption 
of particles (and liquid containing particles) to the container, pipette tip and instrument 
tubing. After the entire suspension of 0.1 mg/mL PMMA beads was measured (after 22 
minutes), 5 post-sample rinsing steps of 0.5 mL each were applied, as described in the 
Methods section. As seen from the results in Figure 3A, over the whole measurement 
including the rinsing steps PMMA beads of about 15 µm were detected. 
Although fewer particles were detected when the rinsing fluid passed through the flow cell 
and was being measured (see drop in particle volume after 22 minutes), still substantial 
amounts of particles were included in the measurement when rinsing was applied. Figure 
3B shows that less than 80% of the total particle volume found in suspension had passed 
the camera view at the moment when the first 0.5 mL of rinsing fluid was added. Only after 
3 rinsing steps were applied, almost all particles found in the suspension had passed the 
camera view. 
Figure 3: The effect of post-sample rinsing steps during the MFI measurement on analysis of 
adsorbed particles (and liquid containing particles) to the tubing and pipette tip. A: Particle 
size (mean and standard deviation; red circles) and total particle volume (mean and standard 
deviation; black squares) at different time points. The latter is achieved through multiplication 
of the particle count and single particle volume at given time points. Single particle volume is 
calculated from the average particle size and formula for volume of a sphere. B: Cumulative 
particle volume at different time points during the measurement expressed in percent, with 
100% being the total particle volume measured in the experiment. The red arrows indicate 
the time points at which 0.5 mL of particle free suspending fluid was used to rinse the tubing, 
pipette tip and subsequently measured by MFI, as described in Methods section. 
Therefore, for the following studies we have applied 3 post-sample rinsing steps with 
0.5 mL of the particle free suspension in order to measure the particles adsorbed to the 
tubing and pipette tip. 
Porosity measurements of PMMA beads (method validation)
For the validation of the presented method for porosity determination we used PMMA 
beads. Based on the previous experiments, the following conditions were used: the beads 
were suspended at a PMMA concentration of 0.1 mg/mL in a suspending fluid of PBS-T with 
0.63 g/mL CsCl (and a density of 1.15 g/mL), the sample volume was 5 mL, and 3 0.5-mL 
post-sample rinsing steps were applied. 
The measurements resulted in a measured density of 1.17 ± 0.03 g/mL and a derived 
porosity of 2 ± 2% for the studied PMMA beads. These values are in excellent agreement 
with the given information by the manufacturer (density of 1.19 g/mL, 0% porosity). 
Porosity measurements of PLGA microparticles (method application)
Figure 4: Examples of MFI pictures of individual particles in batch A and G of the studied 
PLGA microparticles. Batches B-F had particles looking similar to the ones from batch A. The 
scale bar at the right bottom depicts 100 µm.
The developed method was applied for determination of the porosity of 7 different batches 
of PLGA microparticles. Based on the MIP measurements these batches differed in porosity 
(see Table 1). For each PLGA microparticle batch the particle concentration was optimized 
according to the previous section. Briefly, the optimal concentration was chosen such that 
the percentage of non-isolated particles was lowest. In order to keep the measurement 
duration not more than 40 minutes per sample the suspension volume was limited to 5 mL. 
The optimal fluid density was based on the expected density of each PLGA microparticle 
batch when suspended in the liquid (calculated from the loading and porosity value derived 
with MIP). Given the almost similar density of the API and the PLGA raw material, for all 
the suspensions the same fluid density was used. The chosen fluid density differed less 
than 3% from each (expected) PLGA microparticle density. A summary of these suspension 
conditions and measured average and standard deviation of the particle sizes are given in 
Table 2. All the batches contained predominantly spherical particles, except for batch G, 
which showed more unevenly shaped particles (Figure 4). In Figure 5, the average and 
standard deviation of the calculated porosity (n = 3) values are plotted against the values 
obtained by MIP, illustrating that the results from the developed flow imaging microscopy 
based method are in excellent agreement with the ones found by MIP. The line shows the 
linear regression (goodness of fit: R2 = 0.9854), with the dashed lines representing the 95% 
confidence interval (CI) range. The 95% CI range of the slope was 1.006 – 1.334, which 
indicates high similarity between the MFI derived and MIP derived porosity. 
Figure 5: Porosity results gained from the MFI 
measurements against MIP derived porosity 
values for seven different PLGA microparticle 
batches. For each batch the mean and standard 
deviation of three measured samples are shown. 
The linear relation between MIP and flow imaging 
microscopy porosity is denoted as the solid line, 
with the 95% confidence of interval of the linear 
relation between the dashed lines.
Table 2: Summary of the conditions used for the studies with the 7 PLGA microparticle 
batches and the size and morphological parameters obtained by MFI.
*Significantly different from the other batch(es) (one-way Anova (p<0.0001) followed by 
post-hoc Tukey’s multiple comparison test (p<0.05))
Discussion
The porosity of PLGA microparticles has been recognized as an important parameter 
for the release kinetics of the encapsulated drug4,11. Currently, MIP is the most employed 
method for porosity measurements. Considering the limitations of the MIP method, there 
is a need for a more straightforward method. In this investigation we have developed a 
flow imaging microscopy based method using PMMA microparticle beads and applied the 
developed method for porosity determination of a number of PLGA microparticle batches. 
Our method depends on the precision and accuracy of two parameters that are included 
in the calculations, namely the mass of the particles used for the suspension preparation 
and the total particle volume as measured by MFI. The error in the weighing was minimized 
by the use of a microbalance for the masses of about 1 mg used for our measurements 
(translating into a theoretical weighing error of about 0.01%). However, other factors 
related to sample preparation and measurement also contribute to the overall error in the 
measurement and determination of the total particle volume. 
The calculation of particle volume is based on the size distribution of the sample. For high 
accuracy of the latter parameter, a flow imaging microscopy technique with high sizing and 
counting accuracy is essential. The sizing accuracy of MFI was shown to be high for small 
polystyrene beads (2 – 10 µm)12. In a separate study we found that the sizing accuracy larger 
(30 – 70 µm) NIST-traceable polystyrene beads was also high (see Supplementary Table 
1). Zölls and coworkers found high counting accuracy, which was suggested to be a result 
of high sample efficiency of the MFI 5200 system (about 85%)12. The counting accuracy 
depends on the concentration and size of particles in the measured sample. Therefore, 
the manufacturer of the MFI provides concentration limitations for different particle sizes 
up to 10 µm, with respect to the counting accuracy of the system, with a recommended 
maximum concentration of 20,000 10-µm particles per mL13. In our study we have shown 
that this recommendation is also valid when total particle volume determination is the 
ultimate goal of a measurement. We found that the total particle volume calculation (from 
the average particle size and concentration) was accurate up to a (15-µm sized) PMMA 
bead concentration of 0.5 mg/mL, which corresponds to about 24,000 particles per mL. 
One caveat with respect to volume determination of microparticles is that any significant 
swelling of the particles would lead to overestimation of the original size and total particle 
volume, which would consequently result in underestimation of the porosity. However, it 
has been shown that, for PLGA particles, detectable swelling appears at the later stages 
of the degradation, that is after several days when the molecular weight of the PLGA 
matrix gets lower than 20 kDa14. Including studies on optimizing the condition and replicate 
measurements the achievement of porosity value as presented in our investigation does 
not cost more than a couple of hours. 
MFI derives the size of a particle from the measured particle area, by calculating the 
diameter of a circle with an equivalent projected surface area. In case of PLGA microparticles 
the nearly spherical shape reduces the chance of inaccurate sizing. However, optically 
overlapping particles and aggregates (possessing mostly non-spherical shapes) are 
more subjected to inaccurate sizing. The amount of non-isolated particles detected in the 
suspension was found to mainly depend on the particle concentration. More particles per 
volume unit of the liquid obviously lead to a higher chance that multiple particles would 
coincidentally overlap in the field of view. In some cases particles that are too close to 
each other in the field of view (but still obviously physically separated), are erroneously 
detected as one agglomerate (e.g., see rightmost particle image in Figure 2). Probably this 
is caused by a combination of light diffraction from two particles close to each other and a 
very sensitive detection threshold used by the MFI software. This threshold together with 
the so-called minimum distance-to-the-neighbor setting in MFI (by default 3 µm), results 
in detection of the pixels between these particles as part of the agglomerated particle13. 
Naturally, the detected non-isolated particles may also be real aggregates, meaning that 
the microparticles are physically bound to each other. 
Measures can be taken to reduce the chances of optically occluded particles and presence 
of real particle aggregates in the PLGA microparticle batches. For the latter surfactants 
present in the suspending agent, vortexing steps and sonication should in principle 
reduce physical aggregation. For PLGA microparticles it is well known that the tendency 
of microparticles to aggregate on drying is related to the extent of the particle hydration 
and the residual ethyl acetate in wet microparticles15. According to the manufacturer, the 
residual solvent content in the different batches of the microparticles were measured to be 
of insignificant value (below 0.1%). 
Reduction of the particle concentration in order to reduce the chance of overlapping particles 
in the field of view has its limitations. Namely that a very large volume of suspension must 
be measured to make sure that a high number of particles is counted. Therefore, it is 
necessary to define a threshold for the amount of non-isolated particles (relative to the total) 
that still delivers accurate particle volume determination. The threshold for this amount of 
non-isolated particles we had set at 30%. This threshold was based on our study with the 
PMMA beads, where even up to 30% (volume-based) non-isolated particles accurate total 
particle volumes were achieved (see Figure 2B). At the end the volume percentage of non-
isolated particles for the studies with PLGA microparticle was not more than 12%. 
These theoretical facts combined with our observations, brings us to the conclusion that, 
in order to reduce the error introduced by the non-isolated particles, low microparticle 
concentrations should be used for the MFI measurements. One should keep in mind that 
very low concentrations would require analysis of large suspension volumes to detect a 
sufficiently large number of particles (in this study the choice was detection of at least 50,000 
particles in total) for the statistical power of the analysis. Analysis of large volumes would 
require tremendously prolonged measurement times. Therefore, finding a compromise 
between particle concentration, statistical power and measurement time is necessary for 
individual batches to be measured. In our study, typical analysis times per sample were 
between 20 – 40 minutes. 
Decreasing the concentration of a microparticle batch with a broad size distribution cannot 
fully assure that coincidental particle overlap in the field of view will not occur. This has to 
do with the sedimentation of particles during the measurements. Particulate sedimentation 
in a fluid depends mainly on the size of the particle and the density difference between the 
particle and the fluid16. In case of a sample containing a broad size distribution (e.g., PLGA 
microparticles), a big density gap between the particles and the suspending fluid will lead 
to rather fast settling particles. Since larger particles will settle faster, this can create locally 
high concentrations of (in particular large) particles. Decreasing the density difference 
between the particle and the fluid is an effective way to avoid this phenomenon. Cesium 
chloride is known to be an inert salt and has the great advantage of being able to change 
the density of aqueous solutions with very limited change in the viscosity17, and therefore a 
good choice to be used for adjusting the fluid density. 
Our results presented in Figure 1 clearly indicate that the bigger the difference between 
the density of the particle and the suspending liquid, the higher the chance of sample 
heterogeneity. This heterogeneity caused by settling/floating of particles during measurement, 
would hypothetically result into locally high numbers of non-isolated particles. We have 
proven this hypothesis for the condition where we had the largest gap in density between 
particle and the suspending liquid, i.e., for the PMMA microparticle beads suspended in a 
CsCl free solution with a density of 1 g/mL. The low counts at start are caused by dilution 
with particle free liquid that was used to perform the ‘optimize illumination’ step and the 
low counts in the last part of the measurement are caused by creation of locally decreased 
particle concentration due to settling of particles earlier during the measurement. We have 
calculated the volume percentage of non-isolated particles at each time point, excluding 
the first and last minutes of the run where the low number of particles compared to the rest 
of the run could result in unreliability in calculation of the percentage of aggregates. The 
data in the Supplementary Figure S1 indicates that the percentage of non-isolated particles 
resembled a parabolic shape over the course of MFI analysis. This confirms the above-
mentioned hypothesis that the settling of particle during the experiment can cause a locally 
high concentration of non-isolated particles (i.e. the peak of the parabola). Consequently 
this could lead to larger errors in estimation of the total volume of the particles. 
Both the suspending medium and the PMMA particles may interact not only with the 
container, but also with the pipette tip on top of the MFI inlet port and the MFI tubing. This 
is also evident from the results in Figure 3A, where the first part of the measurement has a 
lower total particle volume than the rest of the measurement until post-rinsing steps. This 
could be overcome by a post-sample rinsing step with particle free suspending medium: 
the expected porosity (0% for control PMMA particles) was reached after 3 rinsing steps 
were included in the measurement. The tendency of suspending medium and suspended 
particles to interact with the tip and tubing materials will determine these rinsing conditions. 
Despite the attempts presented here, it appears to be difficult to have a homogenous 
suspension throughout the whole measurement. Also the loss of particles due to interaction 
with the tip and tubes would jeopardize the accuracy of the method even when fluid density 
is adjusted and a rather long-term homogeneity during the measurement is attained. 
Therefore, the presented method cannot be further simplified by calculating the particle 
volume (per volume of suspension) from a specific fraction of a MFI measurement; rather, 
it is advised to measure the entire sample and include post-sample rinsing steps to ensure 
measurement of all the particles within that sample. 
After validation of the method with PMMA beads, we were able to find fairly similar porosities 
for 7 batches of PLGA microparticles compared to MIP derived ones. That is seen from the 
average slope of the linear regression that had a value of 1.17 ± 0.06. Our investigation 
shows also that the method can be applied for a considerably wide range of porosities. 
For the batch with the highest MIP derived porosity (batch G), we found a relatively large 
standard deviation of the measured particle porosity. The reason for this is likely the non-
spherical shape of the particles, resulting in irreproducible sizing and hence total particle 
volume determination. The latter is also obvious from the aspect ratio value, which is lower 
for batch G compared to all the other PLGA microparticle batches (see Table 2). 
Overall, the method we propose in this study is very applicable as a tool to assess the 
porosity of microparticles. In addition, the instrument delivers particle size distribution of 
the batch and images of the particles as well as several morphological parameters. For 
the porosity determinations certain preparatory studies, as we described here, need to be 
performed in order to achieve accurate measurements. 
Conclusion
In this study, we have investigated a novel method for the porosity determination of 
microparticles based on measurement using MFI. We have shown that optimization of 
the particle concentration, suspending fluid density and post-sample rinsing steps during 
measurement are advisable for obtaining the most reliable porosity outcome. The described 
method allowed for successful measurement of the porosity of (spherical) PMMA beads 
and 7 different PLGA microparticle batches. The method requires only a few milligrams of 
the particle powder, which is an asset for early stage formulation and process development 
operations. 
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Supplementary Information
The sizing accuracy of MFI was tested for bead larger than 10 μm. Therefore, 3 NIST-
traceable polystyrene beads were used of different sizes (mean ± standard deviation), 
namely 29.8 ± 0.4 µm; 50.2 ± 0.5 µm; 69.1 ± 0.8 µm. The results are shown in Supplementary 
Table 1. The measured values for each bead size were compared with the size provided by 
the manufacturer (using a paired t-test). All MFI derived sizes were shown to be statistically 
similar (p > 0.05) to the manufacturer’s specifications. 
Supplementary Table 1: Sizing accuracy of polystyrene standards with MFI.
Declared size by the man-
ufacturer (µm)
MFI derived size 
(µm)
P value
29.8 ± 0.4 29.7 ± 0.1 < 0.0001
50.2 ± 0.5 50.1 ± 0.1 < 0.0001
69.1 ± 0.8 69.0 ± 0.2    0.0001
Supplementary Figure 1: Percent of non-isolated 
particles (based on volume) detected at each time 
point of the measurement presented in Figure 1A 
of the main document. 
A label-free method for cell counting and viability 
determination using flow imaging microscopy 
A.S. Sediq1, R. Klem1, M.R. Nejadnik1, P. Meij2, W. Jiskoot1,*
1 Division of Drug Delivery Technology, Cluster BioTherapeutics, Leiden Academic Centre for Drug 
Research (LACDR), Leiden University, Leiden, The Netherlands                                          




Two quality attributes of cell therapy products are cell concentration and percentage of 
viable cells. Despite the availability of techniques to determine cell concentration and 
viability, there is a need for label-free, robust and user-friendly techniques. In this study we 
have investigated the potential of two flow imaging microscopy (FIM) techniques (Micro-
Flow Imaging (MFI) and FlowCAM) to determine cell concentration and viability. For this 
goal we have exposed B-lineage acute lymphoblastic leukemia (B-ALL) cells of 2 different 
donors to ambient conditions, in order to induce cell death. Samples were taken at different 
days and measured with MFI, FlowCAM, hemocytometry and automated cell counting. 
Dead and live cells from fresh B-ALL cell suspension were fractionated by flow cytometry in 
order to derive filters based on morphological parameters of separate cell populations with 
MFI and FlowCAM. The filter sets were used to assess the concentration of viable cells in 
the measured samples. All techniques gave fairly similar cell concentration values over the 
whole incubation period. However, MFI showed to be superior with respect to precision. Both 
FIM methods were able to provide similar results for viability as the conventional methods 
(hemocytometry and automated cell counting). Altogether, our investigation shows that 
FIM-based methods may be advantageous over conventional methods, as FIM measures 
much larger sample volumes, does not require labeling, is less laborious and provides 
images of individual cells. The latter asset we have successfully used to determine viability, 
but can potentially be employed to distinguish early stages of cell death and different cell 
types in a heterogeneous cell sample.  
Introduction 
Cell therapy products (CTPs) are receiving increasing attention by the pharmaceutical 
industry because of their demonstrated potential for use in treatment of a variety of diseases, 
such as cancers, viral infections, and autoimmune disorders1,2. The quality of CTPs relies, 
among others, on the viability of the cells. During production, cells used for cell therapy may 
undergo different process steps, such as harvesting, purification, genetic manipulation, 
expansion, freezing and thawing3. These procedures, as well as other treatments, such 
as transport4 and storage in infusion medium/solution5, and even the administration to 
the patient 6, can induce different types of stresses to the cells and potentially affect cell 
viability. While there are some regulations on what properties of CTPs should be tested7, 
quick testing of viability prior to administration to the patient is often neglected. As a result, 
changes in product quality that might occur between production and administration could 
remain undetected. 
Two main techniques that are frequently applied to assess cell viability are hemocytometry8 
and flow cytometry9. The determination of cell viability with a hemocytometer is based 
on staining of the dead cells using dyes like eosin and trypan blue8. In a flow cytometer 
a laser beam is focused on a flowing liquid. Individual cells in the flow scatter the laser 
light and are detected by the system. The type, size and other characteristics of the cells 
determines the degree of the scattering. The forward scatter (FSC) and side scatter (SSC) 
provide information about cell size and granularity, respectively. Granularity level has 
been shown to be inversely related with cell viability10. Intrinsic fluorescence of the cells 
and/or fluorescence from a fluorescent label can also be detected11. Moreover, the use 
of fluorescently labeled antibodies directed against cell surface markers can aid in the 
evaluation of cell type and viability. Flow cytometry is known to be a very accurate and 
reproducible technique for cell viability tests. However, absolute cell concentrations are 
usually not easily obtained. In addition, the preparation and labeling of the cells can be 
time-consuming and expensive. 
Hemocytometry is the currently the gold standard in the clinical practice for cell counting 
and viability determination. Whilst being a fast method, the method can be laborious 
and has certain weak points that could potentially harm the accuracy of the method. For 
example, the pipetting of the cell suspension and fitting the cover glass may disrupt the 
sample homogeneity at the cytometer surface. In addition, the method uses only a few 
microliters of the suspension for the actual counting of the (viable and non-viable) cells and 
extrapolates this number to a concentration unit of cells per milliliter. With respect to the 
quantity of cell suspension measured and the laborious nature of the method, automated 
cell counters provide improvement, especially for routine measurements, as they measure 
about 4x as much volume as a hemocytometer (0.4 vs. 0.1 μL). However, one should be 
aware that non-cellular particles in the sample could be counted as a cell as well. 
In this regard, less laborious, inexpensive techniques that allow for rapid and reliable 
counting of CTPs would be extremely beneficial for improving the success of CTPs in 
clinical practice. Emerging flow imaging microscopy (FIM) techniques may fulfill these 
needs. In these systems the sample flows through a flow cell where images are taken with 
a high-magnification digital camera. With the help of the dedicated instrument software, the 
quantity and several morphological parameters of the particles can be extracted from the 
images12. FIM can give valuable information about cells, without the need for labeling, and 
detect small changes in cell size and morphology which have been shown to be related to 
cell viability13,14. In addition, FIM techniques are generally easy and fast to perform. 
One of these FIM techniques is Micro-Flow Imaging, which owes it popularity in this field 
mainly to its user-friendliness and robust operation. The application of MFI for cells is 
limited but not unexplored. For instance, Martin et al. have used MFI to study aggregation 
tendency of thawed hematopoietic stem cells15. A recent study of Farrell and coworkers 
used MFI to determine cell coverage and confluency on microcarriers used in culture-
derived bioreactors16. Besides MFI, FlowCAM has been explored for its potential in biologic 
drug product development17-19 and drug delivery systems (Chapter 4). 
The aim of this study was to evaluate the performance of two FIM techniques, i.e., Micro-
Flow Imaging (MFI) and FlowCAM, in their ability to determine cell viability. Even though 
the devices are based on the same measurement principle, they differ in several aspects. 
The FlowCAM has a higher resolution and provides more particle parameters, whereas 
the MFI tends to provide a more accurate determination of particle concentration19,20. In 
the presented study, the two systems are used for the characterization of two cell lines and 
compared with hemocytometry and automated cell counting as well as with each other. 
Materials and methods
Cell materials
B-lineage acute lymphoblastic leukemia (B-ALL) cells were used as model cells in this 
study. The cells were cultured from two different donors (ALL-CR and ALL-CM21; further 
referred to as cell line 1 and cell line 2) and provided by the Department of Hematology, 
Leiden University (LUMC, Leiden, the Netherlands). Cells were frozen in 60% v/v wash 
medium (BioWhittaker® Iscove’s Modified Dulbecco’s Medium (IMDM) 98.5% v/v, penicillin/
streptomycin (Lonza) 1% v/v, HSA-20% 0.5% v/v) and a final concentration of 10% v/v 
HSA-20%, 10% v/v DMSO (LUMC, Leiden, the Netherlands) at a concentration of about 
1∙107 cells/mL and stored at -80˚C until the start of incubation experiments. After controlled 
thawing, washing and counting, cells were suspended in NaCl 0.9% m/v + HSA-20% 
2% v/v at a concentration of 106 cells/mL and were exposed to the stress condition described 
below.
Stress condition
The chosen stress condition in which the cells showed a clear decrease in, but not a 
total loss of viability, was incubation at ambient temperature for up to 8 days. The cell 
concentration and morphological parameters of each sample were analyzed at different 
days by using MFI and FlowCAM. For cell line 1 the measurements were performed at 
day 0, 1, 2, 4, 6 and 8. The study performed with the 2nd cell line served as a confirmative 
study and therefore the measurements at day 4 and 6 were not performed. In parallel, the 
cell concentration and number of viable cells in the same samples were determined with a 
hemocytometer and an automated cell counter. For the data analysis of both flow imaging 
microscopy techniques we only included particles detectable with the hemocytometer and 
the automated cell counter, i.e., particles ≥4 µm.
Hemocytometry
Cell suspensions were diluted twofold with a trypan blue solution (0.4% (w/v) in 0.81% 
NaCl and 0.06% K2HPO4 (Bio-Rad, Hercules, California, USA)). Ten µL of the mixture was 
placed on a Bright-Line hemocytometer glass (Sigma-Aldrich, Steinheim, Germany), and 
analyzed by using a light microscope (Zeiss Axiostar Plus, Carl Zeiss Light Microscopy, 
Göttingen, Germany). Both viable (not stained) and non-viable (stained) cells were counted 
in 25 frames of the hemocytometer according to the manufacturer’s recommendations 
and the percentage of viable cells to the total was calculated22. For each sample triplicate 
measurements were conducted. 
Automated cell counting
Ten µL of the mixture prepared for the hemocytometry was introduced into the counting 
slide. Subsequently, the cell concentration and percentage of viable cells were measured 
by using a Bio-Rad TC20 Automated Cell Counter (Bio Rad, Hercules, California, USA). 
This procedure was repeated three times for each sample.   
Micro-Flow Imaging (MFI)
In order to decrease the concentration of the cells and reduce the chance of detection of 
overlapping particles, samples were first diluted 4-fold with the particle free NaCl 0.9% m/v 
+ HSA-20% 2% v/v . The diluted samples were analyzed by using a Micro Flow Imaging 
5200 (Protein Simple, Santa Clara, CA, USA), with MFI View System Software (MVSS) 
Version 2. No filters were applied during the runs. The 100 μm silane coated flow cell 
was rinsed with flow of ultrapure water (18.2 MΩ.cm; dispensed by using a Purelab Ultra 
water purification system (ELGA LabWater, Marlow, UK) and thereafter a background 
measurement was taken with particle free NaCl 0.9% m/v + HSA-20% 2% v/v. For the 
analysis, 0.50 ml of each sample was run at a flow rate of 0.17 mL/min. The data analysis 
was performed with MFI View Analysis. 
Table 1: Morphological parameters used in this study and their descriptions asprovided by 
MVAS (MFI) and Visual SpreadSheet (FlowCAM).
Suite (MVAS) Version 1.2. Table 1 summarizes the main morphological parameters provided 
by the MVAS and their descriptions. The size distribution of each sample was presented 
in equivalent circular diameter (ECD). Each sample was measured three times with MFI.
FlowCAM
The second flow imaging technique used in this study was a FlowCAM VS1 (Fluid Imaging 
Technologies, Yarmouth, ME, USA). After rinsing the FC50 flow cell with ultrapure water, 
100 μL of each 4-fold diluted sample was run at a flow rate of 0.030 ml/min controlled by a 
C70 syringe pump. Images were taken with a Sony XCD-SX90 camera at 22 fps (shutter: 8, 
gain: 224, 20x lens). The data were analyzed by Visual SpreadSheet Version 3 and a filter 
for area-based diameter (ABD > 4µm) was applied. Aspect ratio (> 0.3) and circle fit (> 0.1) 
were also chosen to exclude impurities with non-circular shapes. No additional filters were 
applied for derivation of total cell concentration. However, for study of the morphological 
parameters associated with non-viable cells and subsequent viability determination of 
different samples, additional filters were used. In order to remove edge particles (particles 
that were detected at the borders of the camera field, hence imaged partially), the acceptable 
detection field was reduced to 95 – 1183 and 6 – 952, respectively, for left-right and top-
bottom orientations. The edge gradient parameter provided by FlowCAM was used to 
exclude out-of-focus particles. The acceptable range for edge gradient was determined in 
a preliminary study. In Table 1, descriptions of the main morphological parameters provided 
by the Visual SpreadSheet are given. It is worth mentioning that the FlowCAM can calculate 
the particle size through two different algorithms. In our study we chose to proceed with the 
area based diameter (ABD) only, because the principle of ABD and ECD is similar.
Fluorescence-activated cell sorting (FACS)
Flow cytometric cell sorting (FACS) on a FACSAria III (BD Biosciences, New Jersey, 
USA) was used to separate dead and/or dying cells from living cells based on the forward 
scatter (FSC) and side scatter (SSC) ‘live gate’ as shown in Supplementary Figure S1. The 
presumably dead and live cells that were collected with the FACS were then measured with 
MFI and FlowCAM. These FIM data were used to develop data filters for dead and live cells 
for each FIM technique. For this purpose the parameter that showed highest difference 
(for both instruments the size) between live and dead cells, was used as a primary filter. 
After applying this primary filter, the changes of all the other parameters were monitored. 
Consequently, threshold values for all the other parameters could systematically be fine-
tuned. At the end, the filters were tested on the analyzed sorted fractions and FIM derived 
viability was compared to the trypan blue assisted values found for each cell sample. 
Results 
The two B-ALL cell lines were thawed, analyzed and then left at ambient temperature for 8 
days and analyzed at predetermined time points, as described in materials and methods.
Monitoring cell concentration over the eight-days study period
Figure 1: Total cell concentration of (A) cell line 1 and  (B) cell line 2 measured at different 
time points during an 8-day incubation period, as measured by hemocytometry (black), 
automated cell counting (red), MFI (yellow) and FlowCAM (blue). Error bars represent the 
standard deviation of triplicate measurements with each technique.
Figure 1 shows the total (live and dead) cell concentrations as measured with all four 
techniques over the 8-days study period, for both investigated cell lines. The results indicate 
that all the techniques gave fairly similar cell concentrations. FlowCAM appeared to have 
the lowest precision, followed by hemocytometry, as judged by the standard deviations. 
The cell concentration of the cell line 1 showed a decreasing trend over time, whereas for 
cell line 2 the cell counts remained fairly stable. 
Morphological parameters of B-ALL cells monitored with FIM techniques
Both flow imaging microscopy techniques provide morphological parameters of the detected 
particles (including cells) obtained from the individual images. A few representative images 
of individual particles detected by the two FIM techniques are shown in Figure 2. It is 
obvious that FlowCAM has a much higher lens magnification, as seen from the size of 
the image being larger for the same cell sizes measured with MFI. The high resolution 
images of FlowCAM compared to MFI may result in the ability to derive more morphological 
parameters using FlowCAM than MFI. Nevertheless, some of the most relevant parameters 
allowed a comparison of FlowCAM with MFI (see Table 1). In our 8-days study we monitored 
changes in all the 5 parameters listed in Table 1 for the studied cells. 
Figure 2: Representative images of the cells detected by MFI (middle column) and FlowCAM 
(right column). The cells are categorized in three size ranges as shown in the left column.
Figure 3: Overview of the changes in different morphological parameters, including size 
(equivalent circular diameter), of cell line 1, as observed with MFI, during the incubation 
study. Different line colors represent measurements at different days. For each parameter the 
frequency distribution of the corresponding parameter unit range is shown.
Figure 3 shows the distribution of particles over the parameters derived from the MFI 
analysis for cell line 1 during the 8-days incubation study.  The size distribution graph 
shows that there was a decrease in the number of the larger particles and an increase 
in the number of smaller particles over time. The peak around 8 µm in the distribution 
of day 1 slowly descended, while a new peak around 6 µm rose and became apparent 
at day 8. The intensity frequency graphs showed a similar trend. Fresh cell suspension 
showed pronounced peaks around 490 and 210, respectively, for the mean and standard 
deviation of intensity. Incubation over time resulted in a decrease of aforementioned peaks 
and appearance of two other peaks in each graph, namely at 560 and 730 for the mean 
intensity and at 50 and 180 for the standard deviation of the intensity. For the shape related 
parameters, i.e., circularity and aspect ratio, only the latter showed distinctive changes in 
its distribution graph. The aspect ratio value started to decrease and deviated further from 
1 over time. The same trend in ECD and intensity mean was observed for cell line 2 (see 
Supplementary Figure S2). The intensity standard deviation for cell line 2 showed only a 
decrease and broadening in the main peak, whereas the changes in the shape related 
parameters were not considerable. 
Figure 4: Overview of the changes in different morphological parameters, including size 
(area based diameter), of cell line 1, as observed with FlowCAM, during the incubation study. 
Different line colors represent measurements at different days. For each parameter the 
frequency distribution of the corresponding parameter unit range is shown.
The distribution of particles over the parameters studied with the FlowCAM is shown in 
Figure 4. The change in the ABD size distribution was fairly similar to the changes seen in 
the ECD size distribution with MFI. Fresh cell sample showed a distinct peak at about 12 
µm and over time this peak disappeared and was replaced by relatively broad peak at a 
smaller size range (around 6 µm). However, there was also a third transient peak at about 
8 µm seen, which was already present in the fresh sample and increased after 24 hours, 
and then diminished in the following days. In contrast to MFI, with FlowCAM the changes in 
the particle intensity were not monitored (further explained in the Discussion section), and 
the focus was only put on four shape related parameters. All these parameters showed a 
distinct peak with a value close to 1 for fresh cell sample, which gradually decreased over 
days. For symmetry and circle fit a broad peak at about 0.3 and 0.45, respectively, rose 
and for circularity a narrower peak with a value of 0.2 appeared. Noticeably, for the aspect 
ratio the frequency distribution did not change considerably after 24 hours of incubation. 
For cell line 2, all the studied morphological parameters followed a similar trend, although 
the changes were less pronounced (see Supplementary Figure S3). 
Fractionation and FIM derived morphology of dead and live cells
The fresh cell suspension of the first cell line was analyzed with a flow cytometer to derive 
an appropriate gate for sorting dead and live cells (see Supplementary Figure S1). After the 
fractions of the dead and live cells as identified by flow cytometry were collected, a control 
trypan blue assisted viability test of each fraction was performed on the automated cell 
counter. From these control measurements it was found that the live population contained 
almost 90% viable cells, whereas the dead population contained no more than 20% viable 
cells. For comparison, the unfractionated cell population contained about 75% viable cells. 
The sorted populations were thereafter measured with both FIM techniques to derive the 
values for the different morphological parameters for live and dead cells separately. The 
results are shown in Table 2 and indicate that there was a statistically significant difference 
between the values of each parameter for live and dead cells, except for the circularity 
values derived from MFI and FlowCAM. The R2 values indicate the extent of this difference, 
where a higher R2 indicates a larger difference between live and dead for that particular 
parameter. Thereafter, we defined filters based on the monitored parameters for dead and 
live cells, as shown in Table 3. It has to be noted that although there was no statistically 
significant difference between the values 
Table 2: Derived mean and standard deviation of the morphological parameters provided 
by MFI and FlowCAM for the two cell fractions of cell line 1 sorted using FACS. The 
morphological parameters of the dead and live cells are statistically compared, with the 
results presented in the two rightmost columns.
*Tested morphological parameters: equivalent circular diameter (ECD), intensity mean 
(IntMean), intensity standard deviation (IntSD), circularity (Cir), aspect ratio (AR), area 
based diameter (ABD), symmetry (Sym) and circle fit (CF).
**Derived after applying t-test with GraphPad Prism 5®. R2 quantifies the fraction of all the 
variations in the samples that is accounted for by a difference between the group means. 
n.a. = 0.
of circularity for live and dead cells, this parameter appeared to be distinctive (and useful 
in definition of the FlowCAM filters) when used on top of filters based on other parameters.
Comparing cell viability determination by FIM techniques, hemocytometry and automated 
cell counting
Figure 5: Percentage of viable cells determined with different analytical methods for the cell 
line 1 at different time points during the 8-day incubation period: hemocytometry (black), 
automated cell counting (red), MFI (yellow) and FlowCAM (blue). The error bars represent 
standard deviations of triplicate measurements with each technique.
With the help of the filters for fractionated cells, the percentage of viable cells was calculated 
for both cells at different time points (Figure 5). These percentages obtained from different 
techniques showed similar trends for the viability of both cell lines, i.e., a gradually 
decreasing viability over incubation time. In addition, cell line 2 showed a stronger survival 
potency at the studied incubation conditions (75% decrease in viable cells after 8 days) 
than cell line 1 (50% decrease). 
Discussion
In clinical practice, where CTPs are required to be checked for concentration and viability 
prior to administration, a more rapid and easier method would be highly beneficial. In this 
study we have investigated the potential of two different FIM techniques for this purpose and 
have shown that both techniques can be used to measure the concentration and the viability 
of cells, yielding comparable results to those obtained with conventional hemocytometry 
and cell counting methods. 
The FIM methods, once developed, are easy to perform and do not require staining of 
the cells before the measurement (see comparison made in Table 3). These techniques 
measure a large sample volume and thus count considerably more cells than the 
conventional methods such as hemocytometry. This ability is a great asset for the accuracy 
and precision of both counting and cell viability determination. Another advantage of FIM lies 
in its ability to image individual cells and obtain morphological characteristics of each cell. 
This capability allows avoiding the usage of labels. Moreover, non-cellular materials can be 
manually removed from the data, to avoid inaccurate counting. Furthermore, the imaging 
likely allows the discrimination of different types of cells (and/or non-cellular particles) in a 
heterogeneous population. 
Although hemocytometry, automated cell counting, MFI and FlowCAM are all able to provide 
an estimation of the cell concentration, standard deviations presented in Figure 1 indicate 
that the precision of methods with respect to the cell concentration measurement follows 
this pattern FlowCAM < hemocytometry < automated cell Counter < MFI. For FlowCAM the 
combination of the type of flow cell and image frequencies used in our settings resulted in 
a theoretical analysis efficiency of around 20%, meaning that only 20% of the dispensed 
cell suspension was actually imaged. This limitation in combination with the inability of 
Table 3: Comparison of the different aspects of the techniques evaluated in this study
the analysis package in exclusion of stuck particles that appear in several images from 
the analysis may be the most important contributing factors to the relatively low precision. 
Despite the larger amount of suspension volume measured with the automated cell counter, 
automated cell counting did not show superior precision over hemocytometry with respect to 
cell concentration. This may be caused by the interference of non-cellular material with the 
cell counting. In contrast, MFI resulted in the highest precision. The large amount of imaged 
sample (more than 260 μL vs. 0.1 μL in hemocytometry), high analysis efficiency (about 
85%) and ability to remove stuck particles from being counted multiple times may explain 
the pronounced performance of MFI with respect to the concentration determinations. 
Moreover, precision of hemocytometry may also be affected by the operator, since the 
method requires visual counting and viability assessment based on visual discrimination of 
the color of the cells. 
Monitoring of the total concentration of cell line 1 over time revealed a decreasing trend 
in total cell concentration for all the methods. It is known that the dying and dead cells 
undergo fragmentation into smaller particles23. Presumably these cell debris particles are 
below the lower size limit of the automated cell counting and the lower size limit chosen 
for FIM techniques (4 µm), while in hemocytometry non-cellular particles are visually 
excluded and therefore not counted. FIM data confirm this theory as the ECD and ABD 
size distribution diagrams (Figure 3 and Figure 4) show a clear increase in the number 
of particles below 7 µm over time. This increase was even more pronounced for particles 
below 4 µm, in particular for ECD (Supplementary Figure S4). This observation suggests 
that the FIM techniques are presumably able to detect and count cell fragments as well. 
Analysis of the FIM parameters for incubated cells revealed clear changes in the majority 
of the parameters highlighted in this study, namely ECD, intensity mean, intensity SD and 
aspect ratio for MFI; and ABD, symmetry, aspect ratio, and circle fit for FlowCAM. Both MFI 
and FlowCAM revealed a decreasing trend in the size (ECD and ABD, respectively) of the 
cells during the incubation. Moreover, cells at later time points appeared to have a higher 
intensity, a lower intensity SD and smaller aspect ratios. The latter, together with lower 
symmetry and circle fit values, indicate that the shape of the cells changes towards less 
symmetric and more elongated particles. All these observations point towards a decrease 
in the population of live cells and/or changes in the quality of the live cell population. 
Shrinkage of cell size and changes in cell shape are observed for dead and dying cells 
whose concentration is expected to increase under stress13. Furthermore a decrease in 
the intensity SD can be a sign of disappearance of the cell organelles that contributed to 
variations in intensity of the image in a cell. In order to investigate if all these changes are 
correlated, the data from day 1 and 8 were analyzed further by making 3D plots that show 
the distribution of cells over two MFI derived parameters at the same time (Supplementary 
Figure S5). The peak at 480 a.u. in the intensity mean graph of Figure 3 at day 0 belongs 
to the ECD population around 8 µm (presumably live cells). At day 8 the decrease in cell 
size and increase in cell intensity result in appearance of a new peak with intensity mean 
of 730 and ECD of 6 µm (presumably dead cells). Similar changes in other parameters and 
FlowCAM (Supplementary Figure S6) are observed when the same approach is applied to 
look into different populations based on size. Overall, these correlated changes in all the 
morphology parameters for cell population exposed to stress strongly suggest that MFI and 
FlowCAM are able to pick up early stages of loss in viability that may cause changes in the 
transparency and shape of the cells13. 
Table 4: Specification of the filters used to identify dead and live cells from analysis results 
In order to confirm the capability of FIM characterization for identification of live and dead 
cells and also to define filter conditions that allow quantitative analysis viability separated 
live and dead cells were obtained by FACS and analyzed. After gating and separation of the 
two distinct populations as seen in FSC-SCC plot, the live and dead cells were analyzed by 
both FIM techniques and filter values that allowed distinction of dead from live cells were 
determined. The filters were constructed by setting one value at a time starting from the 
most distinctive parameter until no change was observed in the populations. Filter values for 
MFI data do not include aspect ratio and circularity. After setting the primary filter the values 
of these two parameters did not change that much between live and dead populations. 
Filters for FlowCAM, however, included more parameters including circularity. These filters, 
summarized in Table 4, clearly depict the observations of the incubation experiments. For 
instance the average size and average intensity are smaller for dead cells. 
It has to be noted that the two FIM techniques described herein offer several other 
morphological parameters that could be used in analysis of the cells. However, the 
combination of a high-magnification lens and a thin focus plane of the flow cell results in 
substantial numbers of imaged particles that were out of focus. These particles affect the 
values of a few morphological parameters (e.g., intensity), and therefore were not included 
in our study. 
In our study we aimed to develop a label-free FIM based method to derive viability of 
cells. In order to avoid complexity of the cell sample, we have used a model containing 
one type of cells, i.e., B-ALL cell lines. However, CTPs may contain cells with different 
morphological properties than B-ALL cells or contain multiple cell types. For example, 
different hematopoietic progenitor cell products contain heterogeneous cell population24. 
In principle one can apply the same approach to other cell types and heterogeneous cell 
populations. Therefore, one needs to develop specific filters for each type of cells.
Conclusion
In this study we have investigated the capability of two different FIM techniques, MFI and 
FlowCAM, to be used as a label-free method for cell concentration and viability determination. 
Our data suggests that both methods deliver fairly similar results for concentration and 
quality determination of cellular products as traditional methods, i.e., hemocytometry and 
the automated cell counting. Whereas the MFI method showed a higher precision with 
respect to determination of the cell concentration, the FlowCAM method provides higher-
resolution images. The latter may be useful to identify non-cellular particles and potentially 
discriminate between different types of cells. 
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Supplementary Information
Supplementary Figure S1: Gating strategy for the FACS supported sorting of dead/
dying and viable cells. The graph shows the FSC – SSC plot for the sample containing 
fresh cells from cell line 1. The gated population is considered viable.
Supplementary Figure S2: Overview of the changes observed in different morphological 
parameters as function of incubation time of cell line 2, as observed with MFI, during the 
incubation study. For each parameter the frequency distribution of the corresponding 
parameter unit range is shown.  
Supplementary Figure S3: Overview of the changes observed in different morphological 
parameters as function of incubation time of the cell line 2, as observed with FlowCAM, during 
the incubation study. For each parameter the frequency distribution of the corresponding 
parameter unit range is shown.
Supplementary Figure S4: Changes in MFI and FlowCAM sizing parameters, of cell line 
1, during the incubation study. 
Supplementary Figure S5: Overview of the MFI derived aspect ratio, circularity, average 
intensity and SD intensity for different ECD-based size populations. The x-axis in all the 
graphs shows these populations as 1-µm size bins (from 4 – 15 μm). The y-axis presents 
the concentration of each 1-μm size bin populations relative to the total concentration. In 
the z-plane the average values of different morphological parameters for each size-based 
population is shown. The results for samples of fresh cells (in black) and cells incubated for 
8 days at ambient conditions (in red) are shown. 
Supplementary Figure S6: Overview of the FlowCAM derived aspect ratio, circularity, 
circle fit and symmetry for different ABD-based size populations. The x-axis in all the 
graphs shows these populations as 1-µm size bins (from 4 – 15 μm). The y-axis presents 
the concentration of each 1-μm size bin populations relative to the total concentration. In 
the z-plane the average values of different morphological parameters for each size-based 
population is shown. The results for samples of fresh cells (in black) and cells incubated for 
8 days at ambient conditions (in red) are shown.
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Summary
Complex injectable formulations, such as protein therapeutics1, controlled release systems2 
and cell therapy products3, are gaining a paramount position in the therapy of many life-
threatening and chronic diseases. Most of these products have in common that sub-visible 
particles (SVP), i.e., particulate matter in the size range of about 1 – 100 µm, are critical 
quality attributes. Most protein therapeutics are liquid or freeze-dried formulations in which 
the presence of SVP is unwanted4; many injectable controlled release systems are based 
on particulate drug delivery systems in the sub-visible size range5; and cell concentration 
and viability are important characteristics of cell therapy products6. With the continuous 
improvement of existing and emerging particle analysis techniques, the potentials of these 
tools in addressing current characterization challenges in the field of complex injectable 
formulations have to be investigated. Therefore, the aim of this thesis was to develop 
methods, based on a set of state-of-the-art particle analysis techniques, for characterization 
of pharmaceutically relevant sub-visible particles and to study the value of these methods 
in the characterization of complex injectable formulations. 
Stirring-induced protein aggregation is encountered at different stages of manufacturing of 
biologics. In Chapter 2 we have investigated the cause of this particular type of aggregation 
due to mechanical stress. For this purpose we designed an overhead stirring set-up in 
order to manipulate the presence and magnitude of the contact between the stir bar and the 
container. It was found that contact sliding during stirring initially resulted in the formation 
of submicron protein aggregates (100 – 1000 nm) of tested protein, IgG, as measured by 
nanoparticle tracking analysis (NTA). Continuation of such stirring increased the number of 
aggregates and led to the growth of particles into sub-visible aggregates, as analyzed by 
Micro-Flow Imaging (MFI). Interestingly, no increase in oligomer content was seen in size-
exclusion chromatography (SEC), suggesting a rapid particle formation. Our investigation 
showed that the adjustment of the contact area of stirring and pressure applied by the stir 
bar on the glass surface affected the extent of aggregation. Formation of particles during 
stirring could be prevented by either addition of polysorbate 20 or avoiding contact between 
the solid surfaces. Herewith we have provided new insight into the mechanism of stirring-
induced protein aggregation, by pointing out its root cause and suggesting formulation and 
process strategies to inhibit this route of protein aggregation. 
In Chapter 3 we have used a combination of NTA and MFI to get new insights into the 
kinetics and mechanism of protein-polyelectrolyte complexation. In this study we used IgG 
and dextran sulfate (Mw = 5000) as the model protein and polyelectrolyte, respectively. 
A solution of each with equal mass based concentration was prepared, mixed with the 
other and the resulting mixture was homogenized gently. Samples were taken at different 
time points and analyzed for monomer content and quantity of nano- and microparticles. 
SEC analysis showed that immediately after mixing all the protein was complexed into 
a high number of nanometer sized particles, which was detected, sized and counted by 
NTA. Thereafter, these nanoparticles were reduced in number and increased in size. 
After 1.5 hours microparticles were formed and also these particles continued to grow 
in size and be reduced in number, as observed by MFI measurements. With the help 
of the Smoluchowski’s perikinetic coagulation model7, we fitted the changes in the total 
particle concentration, which enabled us to derive the so-called sticking probability of IgG-
dextran sulfate complexes. The sticking probability is a related to the interaction between 
the protein-polyelectrolyte complexes and can help determination of the growth rate of 
such complexes. We expect that this combination of particle analysis techniques could be 
used also for other systems, such as complexes between polymers and proteins, DNA and 
other biomacromolecules. 
PLGA microparticle porosity is one of the critical parameters that affect the performance 
of these drug delivery systems with respect to the degradation of the particles and release 
of the drug. Our study in Chapter 4 describes a novel method to derive microparticle 
porosity by tracking the sedimentation velocity of suspended particles using a flow imaging 
microscope. Two sedimentation based methods were investigated. In the first method we 
tracked sedimentation velocity of particles in liquids with different densities. Thereafter, 
we (intra- or) extrapolated to the point where the sedimentation velocity would be equal 
to 0. The fluid density value that matched that point was considered to be equal to the 
density of the particles under investigation. This value was then used to estimate the 
porosity with the given size and composition of the particles and the densities of the particle 
constituents. In the second method, we measured the size and sedimentation velocity 
of individual microparticles in a suspending fluid with known density. Then the density of 
the individual particles was calculated by using Stokes’ law of sedimentation and porosity 
values were derived from density. We investigated the influential parameters and validated 
the methods using different sizes of polystyrene standard beads. Using the developed 
method, we determined microparticle porosity of different PLGA microparticle batches, and 
found similar results as the ones obtained by mercury intrusion porosimetry (MIP). 
Chapter 5 introduces another method to derive PLGA microparticle porosity by using MFI. 
In this method, we suspended a known mass of microparticles in a fluid and measured the 
total microparticle volume accurately. The apparent density of particles was easily calculated 
based on the mass/volume ratio. Together with the known composition of the particles 
and the density of the components, we were able to derive the microparticle porosity. 
Parameters affecting the accuracy of the method, such as particle concentration, fluid 
density and particle adsorption to the container and instrument tubing, were investigated by 
using control PMMA beads. These influential parameters were optimized for the analysis of 
7 different PLGA microparticle batches in order to derive the porosity of each. The results 
for all the 7 batches were fairly similar to the ones derived with MIP. The results indicate 
that this method can be used for a reliable assessment of PLGA microparticle porosity with 
only a few milligrams of powder. 
In Chapter 6 we have explored the applicability of flow imaging microscopy (MFI and 
FlowCAM) as a new technique to count cells in a suspension and determine cell viability. In 
this study, we have exposed B-lineage leukemia cells from two different donors to ambient 
conditions for several days, resulting in a reduction of cell viability. During this incubation study 
we measured samples from these cell suspensions with MFI, FlowCAM, hemocytometry 
and automated cell counting. The results from both flow imaging microscopy techniques 
showed changes in cell morphology that could be monitored with a number of parameters 
derived from each instrument. Using fluorescence assisted cell sorting (FACS) we were 
able to separate and collect dead and live cell populations. The morphological parameters 
of the separated dead and live cell populations were determined with FlowCAM and MFI, 
in order to develop morphological filters to discriminate dead and live cells in an unknown 
cell suspension. The filters were shown to be distinctive, as our analyses with flow imaging 
gave similar results for cell viability as the conventional methods (hemocytometry and 
automated cell counting). Also the cell concentration measurements delivered similar, if not 
better, results as hemocytometry and automated cell counting. 
General discussion and perspectives
In the work described in this thesis we have investigated and developed new methods using 
either a combination of particle analysis techniques or a single particle analysis technique. 
All the methods described here have potential to be applied in pharmaceutical research 
and development. 
In our study on protein aggregation induced by stirring (Chapter 2), the power of NTA to 
be able to track early stages of aggregation was shown. Although this method has its 
shortcomings with respect to reproducibility8, it still remains one of the few methods that 
can size and quantify particulate matter in the nanometer size range. Another interesting 
observation from Chapter 2 was the concentration dependent average size of the micron 
sized particles that were formed: at higher protein concentration (0.5 mg/mL) the particles 
were consistently more than 1 µm larger than microparticles formed at lower concentration 
(0.1 mg/mL), as shown by MFI. This observation suggests that MFI is clearly able to reveal 
differences in the low-micrometer range and can be used for studying the kinetics of protein 
aggregation. Ideally, for investigation of the aggregation kinetics one needs to derive mass 
transfer or aggregation rate in relation to the influential parameters9, i.e., for stirring induced 
aggregation the effect of the parameters such as surface area, protein concentration and 
stirring rate (among others) on monomer/aggregate mass balance should be studied. One 
needs to recognize that converting aggregate size distribution to total aggregate mass 
is accompanied with a lot of assumptions with respect to the density of proteins and 
translation of the size to volume10. In this respect, the method for porosity assessment of 
microparticles described in Chapter 4 might also be suitable to derive the density of protein 
aggregates (explained further in this section). 
The method for determining particle growth and concentration presented in Chapter 3 can 
be used to gain insight into the interaction strength between the polyelectrolyte-protein 
particles, which in turn affects the coagulation of complexes. The coagulation process 
continues until the aggregation and disintegration of complexes reach equilibrium, which in 
the end determines the final size of the complexes11. The charge on both components of the 
complexes can be tailored by changing the pH and/or ionic strength of solution12. In addition, 
concentration and ratio of the components have effects on the final size of the complexes13. 
The size of the final complexes determines their potential use in drug delivery14. Altogether, 
it can be concluded that the method presented in this thesis will serve as a valuable tool in 
the screening of the influential parameters on the size of protein-polyelectrolyte complexes. 
In addition, it is worth mentioning that in the field of vaccine product development protein-
polyelectrolyte complexes form an important formulation platform15. The structural interplay 
between antigen and adjuvant in a vaccine formulation resembles same sort of interactions 
as mentioned above. Therefore, characterizing the interaction of these macromolecules is 
crucial for the vaccine potency16. 
Our application of the two different flow imaging microscopy techniques for drug delivery 
systems such as PLGA microparticles shows that the described methods can be of more 
value than porosity determination only. The counting and imaging of the particles in 
suspension brings an important advantage, namely getting information on the morphology 
and size distribution of PLGA microparticles. The high-resolution images of FlowCAM 
result in a high number of observable morphological parameters. In comparison with 
MFI, FlowCAM is a more flexible system, where the operator can practically change any 
setting or aspect of the instrument. The high imaging/analysis efficiency of the MFI can be 
advantageous when rapid and accurate size distribution of the particles is needed. MFI is 
more user-friendly when it comes to the execution of the analysis. Also the supported data 
acquisition mode, MVAS, has certain features (e.g., removing stuck particles) that improve 
the counting accuracy. 
In the development of drug delivery systems there is a need for exploratory studies to 
investigate if the platforms in development can be applicable to obtain a target product profile 
for the drug of interest. Quality-by-Design (QbD) approaches may facilitate development 
of controlled release products, by understanding the impact of the properties of material 
components and manufacturing process on the product quality17.One of the tools in QbD is 
the implementation of process analytical technologies (PAT) during the development. The 
latter concern systems that allow designing, analyzing and controlling the manufacturing 
process, through timely measurements during processing18. In this context, systems such as 
FlowCAM ES® can automatically extract, dilute and run samples from within the production 
or processing line19. This speeds up the production process and delivers continuous data 
to monitor the process and keep track of the quality of the (intermediate) product. 
In addition to using flow imaging microscopy for PLGA microparticles, the sedimentation 
method itself may already be of interest for other types of complex injectable formulations, 
e.g., for the determination of the density of the proteinaceous particles. The density of 
protein aggregates is frequently used to recalculate the number of micron size aggregates 
into mass of protein. In addition, resonant mass measurement (RMM) requires the density 
of aggregates in order to convert the buoyancy of the aggregate into an equivalent circular 
diameter20. Although attempts have been made to determine the aggregate density by RMM 
itself21, the technique does not allow determination of the density of aggregates above 5 
µm. With the sedimentation based method where we use fluids with different density, one 
could possibly attain the density of protein particles larger than 5 µm. 
The last part of this thesis on counting and viability determination of cells (Chapter 6) opens 
a whole new field in the application list of flow imaging microscopy. In the cell therapy 
field knowledge about formulation development is very preliminary, and the availability of 
robust analytical tools that provide cell counts and various morphological characteristics 
can be of great value. In addition, the capability of flow imaging microscopy for cell product 
characterization may be broader than we have shown in our study. High-resolution images 
of FlowCAM may have added value for discrimination of different cells or perhaps a single 
cell at different stages of its differentiation. Moreover, certain FlowCAM models have a 
fluorescence detector that may open new opportunities to analyze fluorescently labeled cells. 
This option may increase the potential of flow imaging microscopy for the characterization 
of cell therapy products. The new application field for flow imaging microscopy that we 
introduced in Chapter 6 is possibly useful directly in a clinical setting. In addition, flow 
imaging microcopy methods could be implemented to test the pharmaceutical quality of 
protein drugs as well as classical parenteral drug dosage forms that are manufactured 
aseptically in hospitals.  
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Appendices
Nederlands samenvatting
Complexe injecteerbare formuleringen, zoals therapeutische eiwitten, gereguleerde-
afgiftesystemen en celtherapieproducten, nemen een steeds belangrijkere positie in bij 
de behandeling van vele levensbedreigende ziektes. Vrijwel alle complexe injecteerbare 
formuleringen hebben als gemeenschappelijk kenmerk dat niet-zichtbare deeltjes (NZD; 
deeltjes met een grootte van ongeveer 1 – 100 µm) een kritisch kwaliteitskenmerk van het 
product zijn. De meeste therapeutische eiwitproducten zijn vloeibare of gevriesdroogde 
formuleringen waarin de aanwezigheid van NZD ongewenst is; vele injecteerbare 
gereguleerde afgiftesystemen zijn gebaseerd op NZD; en cellen zijn levende NZD. Met 
de voortdurende verbetering van bestaande en nieuwe deeltjesanalysetechnieken, is het 
van belang om de toepasbaarheid van deze tools voor de karakterisering van complexe 
injecteerbare formuleringen te onderzoeken. Daarom was het doel van dit proefschrift om 
methodes te ontwikkelen voor karakterisering van farmaceutisch relevante NZD, op basis 
van state-of-the-art deeltjesanalysetechnieken. 
Eiwitaggregatie geïnduceerd door roeren is een fenomeen dat in verschillende stadia van 
de productie van biologische farmaceutische producten plaats kan vinden. In Hoofdstuk 
2 hebben we de oorzaak van eiwitaggregatie als gevolg van roeren onderzocht. Hiervoor 
hebben we een roersysteem ontworpen waarmee het contact tussen roermagneet en 
glasbodem gemanipuleerd kon worden. Uit metingen met nanoparticle tracking analysis 
(NTA) bleek dat het contact tussen roermagneet en glasbodem cruciaal is voor het induceren 
van eiwitaggregatie. Tijdens het roeren van een monoklonaal IgG-oplossing werden 
aanvankelijk submicron eiwitaggregaten (100 – 1000 nm) gevormd, welke na verloop van 
tijd in aantal en grootte toenamen, hetgeen resulteerde in de vorming van NZD, zoals 
geanalyseerd met Micro-Flow Imaging (MFI). Uit size-exclusion chromatography (SEC) 
analyses bleek dat de hoeveelheid oligomeren niet toenam, wat aangaf dat de submicron 
eiwitaggregaten zeer snel gevormd werden. In dezelfde studie hebben we aangetoond 
dat de mate van aggregatie toeneemt bij een vergroting van het contactoppervlak tussen 
roermagneet en glasbodem en een verhoging van de druk uitgeoefend op de glasbodem 
tijdens het roeren. Aggregatie tijdens het roeren kon worden voorkomen door toevoeging 
van polysorbaat 20 of door te roeren zonder dat contact tussen de roerstaaf en de 
glasbodem. Met de uitkomst van deze studie hebben we nieuwe inzichten gecreëerd in het 
mechanisme van eiwitaggregatie als gevolg van roeren. Bovendien hebben we oplossingen 
aangedragen om deze vorm van eiwitaggregatie te onderdrukken door het proces of de 
formulering te optimaliseren. 
In Hoofdstuk 3 hebben we door SEC, NTA en MFI te combineren nieuwe inzichten 
verkregen in de kinetiek en het mechanisme van complexvorming tussen een eiwit en 
een polyelektroliet. In dit onderzoek hebben we monoklonaal IgG en dextransulfaat 
als respectievelijk modeleiwit en polyelektroliet gebruikt. Een mengsel van gelijke 
concentraties (op basis van massa) van IgG en dextransulfaat werd bereid en voorzichtig 
gehomogeniseerd. Monsters werden op verschillende momenten uit het mengsel genomen, 
geanalyseerd op hoeveelheid monomeer (niet gecomplexeerd) eiwit en hoeveelheid nano- 
en microdeeltjes. Uit SEC-analyse bleek dat direct na het mengen van de twee oplossingen 
er geen eiwit in monomere vorm meer in de oplossing aanwezig was. Het eiwit bleek 
gecomplexeerd te zijn in nanodeeltjes, zoals bleek uit NTA, waarmee de concentratie en de 
afmeting van de deeltjes bepaald konden worden. Daarna nam de hoeveelheid van deze 
deeltjes af en werd hun gemiddelde deeltjesgrootte steeds groter. Na 1.5 uur werden de 
eerste microdeeltjes met MFI gedetecteerd, en ook deze namen toe in grootte en namen 
af in aantal. Met behulp van het perikinetische coagulatiemodel van Smoluchowski hebben 
we de veranderingen in deeltjesconcentratie mathematisch kunnen modelleren, waarmee 
we vervolgens de zogenaamde  sticking probability van IgG-dextransulfaatcomplexen 
hebben afgeleid. De sticking probability is gerelateerd aan de interactie tussen de eiwit-
polyelektrolietcomplexen en kan dus helpen bij het bepalen van de groeisnelheid van dit 
soort complexen. We verwachten dat deze combinatie van deeltjesanalysetechnieken ook 
voor andere systemen gebruikt kan worden, zoals complexvorming van polymeren met 
eiwitten, DNA en andere biomacromoleculen. 
De porositeit van PLGA-microdeeltjes is een van de kritische parameters die bepalend 
zijn voor de afbraaksnelheid van het deeltje en het vrijkomen van het geneesmiddel. 
Onze studie in Hoofdstuk 4 beschrijft een nieuwe methode waarmee de porositeit van dit 
soort deeltjes bepaald kan worden, namelijk door het meten van de sedimentatiesnelheid 
van gesuspendeerde deeltjes met behulp van een flow imaging microscope. Twee op 
sedimentatie gebaseerde methoden werden onderzocht. In de eerste methode werd de 
sedimentatiesnelheid van deeltjes in vloeistoffen van verschillende dichtheden bepaald. 
Hierna, hebben we geïnter- of geëxtrapoleerd naar een sedimentatiesnelheid van nul. De 
vloeistofdichtheid die met het nulpunt overeenkwam werd beschouwd als de dichtheid 
van het betreffende deeltje. Deze waarde voor de dichtheid werd dan gebruikt om de 
porositeit, door middel van de bekende deeltjessamenstelling en de dichtheden van de 
grondstoffen van het deeltje, te bepalen. In de tweede methode hebben we deeltjesgrootte 
en sedimentatiesnelheid van individuele deeltjes in een vloeistof met bekende dichtheid 
gemeten. Vervolgens werd de dichtheid van individuele deeltjes berekend aan de hand 
van de wet van Stokes, waaruit daarna de porositeit werd berekend. In dit onderzoek 
hebben we de verschillende factoren die van invloed zijn op het resultaat bestudeerd en de 
methoden met behulp van polystyreenstandaarddeeltjes gevalideerd. Vervolgens hebben 
we de porositeit van verschillende batches van PLGA microdeeltjes bepaald. De gevonden 
waarden kwamen goed overeen met de door middel van mercury intrusion porosimetry 
(MIP) bepaalde porositeiten. 
In Hoofdstuk 5 hebben we een andere methode geïntroduceerd waarmee de porositeit 
van PLGA-microdeeltjes door middel van MFI kunnen worden bepaald. In dit geval hebben 
we een bekende massa van microdeeltjes in een vloeistof gesuspendeerd en hebben het 
totale volume aan deeltjes in de gehele suspensie nauwkeurig bepaald. De schijnbare 
dichtheid van de deeltjes kon gemakkelijk berekend worden door de massa/volume 
verhouding. Samen met het bekende samenstelling van het deeltje en de dichtheid van 
de grondstoffen, konden we de porositeit van het deeltje afleiden. Parameters die van 
invloed waren op de nauwkeurigheid van de methode, zoals concentratie van deeltjes, 
vloeistofdichtheid en adsorptie van deeltjes aan het oppervlak van de beker en buizen 
van het instrument, werden met behulp van PMMA-deeltjes onderzocht. Deze parameters 
werden vervolgens geoptimaliseerd voor de porositeitsbepaling van 7 verschillende batches 
van PLGA-microdeeltjes. De resultaten van al deze batches kwamen goed overeen met 
de door middel van MIP bepaalde porositeiten. De uitkomst van deze studie laat zien dat 
beide methoden geschikt zijn voor het bepalen van de porositeit van PLGA-microdeeltjes, 
met als voordeel dat hiervoor slechts enkele milligrammen microsferen nodig zijn. 
In Hoofdstuk 6 hebben we de toepasbaarheid van flow imaging microscopy (MFI and 
FlowCAM) voor het tellen van cellen in suspensie en het bepalen van hun levensvatbaarheid 
bestudeerd. In dit onderzoek hebben we B-lineage leukemiecellen afkomstig van twee 
verschillende donoren gedurende enkele dagen aan omgevingsomstandigheden 
blootgesteld, om daarmee afname in levensvatbaarheid te veroorzaken. Gedurende deze 
incubatieperiode hebben we op verschillende momenten monsters met MFI, FlowCAM, 
hemocytometrie en een geautomatiseerde cellenteller (TC-20) gemeten. De resultaten van 
beide flow imaging microscopy technieken lieten veranderingen in celmorfologie als functie 
van de incubatietijd zien, zoals bleek uit een aantal morfologische parameters. Door middel 
van fluorescence assisted cell sorting (FACS) waren we in staat om de dode en levende 
cellen te scheiden en deze in suspensie op te vangen. De morfologische parameters 
van de gescheiden dode en levende cellen werden met MFI en FlowCAM bepaald, om 
zodoende softwarefilters te ontwikkelen die onderscheid kunnen maken tussen dode en 
levende cellen in een onbekende celsuspensie. Hiermee bleek het mogelijk om met flow 
imaging microscopy levensvatbaarheidspercentages te verkrijgen die overeenkwamen met 
de waarden verkregen via gebruikelijke methoden (hemocytometrie en TC-20). Bovendien 
bleken de celconcentraties zoals bepaald met MFI, FlowCAM, hemocytometrie en TC-20 
goed overeen te komen, waarbij de reproduceerbaarheid van MFI en FlowCAM superieur 
waren ten opzichte van hemocytometrie en TC-20.
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